

REFINITIV

DELTA REPORT

10-Q

RGNX - REGENXBIO INC.

10-Q - JUNE 30, 2024 COMPARED TO 10-Q - MARCH 31, 2024

The following comparison report has been automatically generated

TOTAL DELTAS	3228
--------------	------

CHANGES	181
---------	-----

DELETIONS	182
-----------	-----

ADDITIONS	2865
-----------	------

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, June 30, 2024**

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 001-37553

REGENXBIO Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

47-1851754

(I.R.S. Employer
Identification No.)

9804 Medical Center Drive

Rockville, MD

(Address of principal executive offices)

20850

(Zip Code)

(240) 552-8181

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	RGNX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 2, 2024 July 25, 2024, there were 49,255,966 49,423,188 shares of the registrant's common stock, par value \$0.0001 per share, issued and outstanding.

[Table of Contents](#)

REGENXBIO INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, JUNE 30, 2024

TABLE OF CONTENTS
[PART I—FINANCIAL INFORMATION](#)

Item 1.	Financial Statements (Unaudited)	3
	Consolidated Balance Sheets as of March 31, 2024 June 30, 2024 and December 31, 2023	3
	Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended March 31, 2024 June 30, 2024 and 2023	4
	Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended March 31, 2024 June 30, 2024 and 2023	5
	Consolidated Statements of Cash Flows for the Three Six Months Ended March 31, 2024 June 30, 2024 and 2023	6 7
	Notes to Consolidated Financial Statements	7 8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22 25
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	30 35
Item 4.	Controls and Procedures	30 35

[PART II—OTHER INFORMATION](#)

Item 1.	Legal Proceedings	32 36
Item 1A.	Risk Factors	32 36

Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	32 36
Item 3.	Defaults Upon Senior Securities	32 36
Item 4.	Mine Safety Disclosures	32 36
Item 5.	Other Information	32 36
Item 6.	Exhibits	33 37
	Signatures	34 38

[Table of Contents](#)

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “anticipate,” “assume,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “objective,” “plan,” “position,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or variations of such words or by similar expressions. We have based these forward-looking statements on our current expectations, estimates and assumptions and analyses in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, uncertainties, assumptions and other important factors, including, but not limited to:

- our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop and commercialize ABBV-RC 314;
- our ability to obtain and maintain regulatory approval of our product candidates and the labeling for any approved products;
- the timing of enrollment, commencement, completion and the success of our AAVIATE[®], AFFINITY BEYOND[®], AFFINITY DUCHENNE[®], ALTITUDE[®], ASCENT[™], ATMOSPHERE[®] and CAMPSITE[®] clinical trials;
- the timing of commencement and completion and the success of preclinical studies conducted by us and our development partners;
- the timely development and launch of new products;
- the scope, progress, expansion and costs of developing and commercializing our product candidates;
- our ability to obtain, maintain and enforce intellectual property protection for our product candidates and technology, and defend against third-party intellectual property-related claims;
- our expectations regarding the development and commercialization of product candidates currently being developed by third parties that utilize technology;
- our anticipated growth strategies;
- our expectations regarding competition;
- the anticipated trends and challenges in our business and the market in which we operate;
- our ability to attract or retain key personnel;
- the size and growth of the potential markets for our product candidates and the ability to serve those markets;
- the rate and degree of market acceptance of any of our products that are approved;
- our expectations regarding our expenses and revenue;
- our strategic pipeline prioritization and corporate restructuring, including plans for advancing our product candidates, the expected charges and savings associated with our restructuring and any future cost reduction measures;

- our ability to execute strategic alternatives for our de-prioritized rare neurodegenerative disease clinical-stage programs;
- our expectations regarding our need for additional financing and our ability to obtain additional financing;
- our expectations regarding the outcome of legal proceedings;
- our expectations regarding regulatory developments in the United States and foreign countries; and
- changes in the financial markets and banking system that may affect the availability and terms on which we may obtain financing and our ability accurately predict how long our existing cash resources will be sufficient to fund our anticipated operating expenses.

[Table of Contents](#)

You should carefully read the factors discussed in the sections titled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the factors discussed elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2023 and in our other filings with the U.S. Securities and Exchange Commission (the SEC) for additional discussion of the risks, uncertainties, assumptions and other important factors that could cause our actual results or developments to differ materially and adversely from those projected in the forward-looking statements. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on us or our businesses or operations. Such statements are not guarantees of future performance, and actual results or developments may differ materially and adversely from those projected in the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we disclaim any duty to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Available Information

Our principal offices are located at 9804 Medical Center Drive, Rockville, MD 20850, and our telephone number is (240) 552-8181. Our website address is www.regenxbio.com. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report on Form 10-Q. We file annual, quarterly, and current reports, proxy statements, and other documents with the SEC under the Exchange Act. You may obtain any reports, proxy and information statements, and other information that we file electronically with the SEC at www.sec.gov.

You also may view and download copies of our SEC filings free of charge at our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference in, and is not considered part of, this Quarterly Report on Form 10-Q. Investors should also note that we use our website, as well as SEC filings, press releases, public conference calls and webcasts, to announce financial information and other material developments regarding our business. We use these channels, as well as any social media channels listed on our website, to communicate with investors and members of the public about our business. It is possible that the information that we post on our social media channels could be deemed material information. Therefore, we encourage investors, the media and others interested in our company to review the information that we post on our social media channels.

As used in this Quarterly Report on Form 10-Q, the terms “REGENXBIO,” “we,” “us,” “our” or the “Company” mean REGENXBIO Inc. and its subsidiaries, on a consolidated basis, unless the context indicates otherwise.

AAVIATE, AFFINITY BEYOND, AFFINITY DUCHENNE, ALTITUDE, ATMOSPHERE, CAMPSIITE, NAV, NAVXCELL, REGENXBIO and the REGENXBIO logos are our registered trademarks. Any other trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

REGENXBIO INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except per share data)

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Assets				
Current assets				
Cash and cash equivalents	\$ 112,975	\$ 34,522	\$ 57,765	\$ 34,522
Marketable securities	225,728	240,736	232,592	240,736
Accounts receivable, net	15,828	24,790	22,809	24,790
Prepaid expenses	13,590	14,520	10,021	14,520
Other current assets	27,297	20,403	23,496	20,403
Total current assets	395,418	334,971	346,683	334,971
Marketable securities	41,807	38,871	36,943	38,871
Accounts receivable	523	701	464	701
Property and equipment, net	127,662	132,103	123,969	132,103
Operating lease right-of-use assets	57,558	60,487	56,344	60,487
Restricted cash	2,030	2,030	2,030	2,030
Other assets	4,217	4,807	2,946	4,807
Total assets	\$ 629,215	\$ 573,970	\$ 569,379	\$ 573,970
Liabilities and Stockholders' Equity				
Current liabilities				
Accounts payable	\$ 31,356	\$ 22,786	\$ 16,362	\$ 22,786
Accrued expenses and other current liabilities	33,129	49,703	42,488	49,703
Deferred revenue	13	148	21	148
Operating lease liabilities	7,066	7,068	7,302	7,068
Liability related to sale of future royalties	38,615	50,567	32,100	50,567
Total current liabilities	110,179	130,272	98,273	130,272
Operating lease liabilities	80,183	82,222	78,234	82,222
Liability related to sale of future royalties	44,702	43,485	41,079	43,485
Other liabilities	3,485	6,249	3,526	6,249
Total liabilities	238,549	262,228	221,112	262,228
Stockholders' equity				
Preferred stock; \$0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—		

Common stock; \$0.0001 par value; 100,000 shares authorized at March 31, 2024 and December 31, 2023; 49,043 and 44,046 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	4		
Preferred stock; \$0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023	—	—		
Common stock; \$0.0001 par value; 100,000 shares authorized at June 30, 2024 and December 31, 2023; 49,317 and 44,046 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	5	4		
Additional paid-in capital	1,162,267	1,021,214	1,171,894	1,021,214
Accumulated other comprehensive loss	(3,229)	(4,429)	(2,266)	(4,429)
Accumulated deficit	(768,377)	(705,047)	(821,366)	(705,047)
Total stockholders' equity	390,666	311,742	348,267	311,742
Total liabilities and stockholders' equity	\$ 629,215	\$ 573,970	\$ 569,379	\$ 573,970

The accompanying notes are an integral part of these unaudited consolidated financial statements.

[Table of Contents](#)

REGENXBIO INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except per share data)

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Revenues						
License and royalty revenue	\$ 15,622	\$ 19,138	\$ 22,295	\$ 19,977	\$ 37,917	\$ 39,115
Total revenues	15,622	19,138	22,295	19,977	37,917	39,115
Operating Expenses						
Cost of revenues	4,283	4,112	10,579	9,475	14,862	13,587
Research and development	54,844	58,516	48,869	59,886	103,713	118,402
General and administrative	18,291	22,634	18,855	23,698	37,146	46,332
Impairment of long-lived assets	2,101	—	—	—	2,101	—
Other operating expenses (income)	(34)	33	29	26	(5)	59
Total operating expenses	79,485	85,295	78,332	93,085	157,817	178,380
Loss from operations	(63,863)	(66,157)	(56,037)	(73,108)	(119,900)	(139,265)
Other Income (Expense)						
Interest income from licensing	37	70	29	40	66	110
Investment income	2,469	2,166	3,468	2,127	5,937	4,293
Interest expense	(1,973)	(2,755)	(449)	(1,120)	(2,422)	(3,875)

Total other income (expense)	533	(519)				
Total other income	3,048	1,047	3,581	528		
Net loss	\$ (63,330)	\$ (66,676)	\$ (52,989)	\$ (72,061)	\$ (116,319)	\$ (138,737)
Other Comprehensive Income						
Unrealized gain on available-for-sale securities, net	1,200	3,779	963	1,524	2,163	5,303
Total other comprehensive income	1,200	3,779	963	1,524	2,163	5,303
Comprehensive loss	\$ (62,130)	\$ (62,897)	\$ (52,026)	\$ (70,537)	\$ (114,156)	\$ (133,434)
Net loss per share, basic and diluted	\$ (1.38)	\$ (1.53)	\$ (1.05)	\$ (1.66)	\$ (2.41)	\$ (3.19)
Weighted-average common shares outstanding, basic and diluted	45,733	43,451	50,601	43,531	48,167	43,491

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

[Table of Contents](#)

REGENXBIO INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(unaudited)
(in thousands)

	Three Months Ended March 31, 2024						Three Months Ended June 30, 2024					
			Accumulated						Accumulated			
			Additional	Other		Total			Additional	Other		Total
	Common Stock		Paid-in	Comprehensive	Accumulated	Stockholders'	Common Stock		Paid-in	Comprehensive	Accumulated	Stockholders'
	Shares	Amount	Capital	Loss	Deficit	Equity	Shares	Amount	Capital	Loss	Deficit	Equity
Balances at December 31, 2023	44,046	\$ 4	\$ 1,021,214	\$ (4,429)	\$ (705,047)	\$ 311,742						
Balances at March 31, 2024	49,043	\$ 5	\$ 1,162,267	\$ (3,229)	\$ (768,377)	\$ 390,666						
Vesting of restricted stock units, net of tax	270	—	(910)	—	—	(910)	39	—	—	—	—	—
Exercise of stock options, net of tax	135	—	884	—	—	884	38	—	192	—	—	192
Issuance of common stock under employee stock purchase plan	27	—	411	—	—	411						

Issuance of common stock and pre-funded warrants upon public offering, net of transaction costs of \$534	4,565	1	131,066	—	—	131,067							
Exercise of pre-funded warrants	197	—	—	—	—	—							
Stock-based compensation expense	—	—	9,602	—	—	9,602	—	—	9,435	—	—	9,435	
Unrealized gain on available-for-sale securities, net	—	—	—	1,200	—	1,200	—	—	—	963	—	963	
Net loss	—	—	—	—	(63,330)	(63,330)	—	—	—	—	(52,989)	(52,989)	
Balances at March 31, 2024	49,043	\$ 5	\$ 1,162,267	\$ (3,229)	\$ (768,377)	\$ 390,666							
Balances at June 30, 2024	49,317	\$ 5	\$ 1,171,894	\$ (2,266)	\$ (821,366)	\$ 348,267							

	Three Months Ended March 31, 2023						Three Months Ended June 30, 2023					
	Accumulated					Total	Accumulated					Total
	Common Stock		Additional	Other	Accumulated		Common Stock		Paid-in	Other	Accumulated	
	Shares	Amount	Paid-in Capital	Comprehensive Loss	Deficit		Shares	Amount	Capital	Loss	Deficit	
Balances at December 31, 2022	43,299	\$ 4	\$ 973,145	\$ (15,401)	\$ (441,553)	\$ 516,195						
Balances at March 31, 2023	43,465	\$ 4	\$ 984,986	\$ (11,622)	\$ (508,229)	\$ 465,139						
Vesting of restricted stock units, net of tax	99	—	(419)	—	—	(419)	28	—	—	—	—	—
Exercise of stock options, net of tax	37	—	471	—	—	471	128	—	749	—	—	749
Issuance of common stock under employee stock purchase plan	30	—	583	—	—	583						
Stock-based compensation expense	—	—	11,206	—	—	11,206	—	—	10,504	—	—	10,504
Unrealized gain on available-for-sale securities, net	—	—	—	3,779	—	3,779	—	—	—	1,524	—	1,524

Net loss	—	—	—	—	(66,676)	(66,676)	—	—	—	—	(72,061)	(72,061)
Balances at March 31, 2023	<u>43,465</u>	<u>\$ 4</u>	<u>\$ 984,986</u>	<u>\$ (11,622)</u>	<u>\$ (508,229)</u>	<u>\$ 465,139</u>						
Balances at June 30, 2023	<u>43,621</u>	<u>\$ 4</u>	<u>\$ 996,239</u>	<u>\$ (10,098)</u>	<u>\$ (580,290)</u>	<u>\$ 405,855</u>						

The accompanying notes are an integral part of these unaudited consolidated financial statements.

[Table of Contents](#)

REGENXBIO INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(unaudited)
(in thousands)

	Six Months Ended June 30, 2024					
	Common Stock		Additional Paid-in Capital	Accumulated		Total Stockholders'
				Other Comprehensive Loss	Accumulated Deficit	
	Shares	Amount	Capital	Loss	Deficit	Equity
Balances at December 31, 2023	44,046	\$ 4	\$ 1,021,214	\$ (4,429)	\$ (705,047)	\$ 311,742
Vesting of restricted stock units, net of tax	309	—	(910)	—	—	(910)
Exercise of stock options, net of tax	173	—	1,076	—	—	1,076
Issuance of common stock under employee stock purchase plan	27	—	411	—	—	411
Issuance of common stock and pre-funded warrants upon public offering, net of transaction costs of \$534	4,565	1	131,066	—	—	131,067
Exercise of pre-funded warrants	197	—	—	—	—	—
Stock-based compensation expense	—	—	19,037	—	—	19,037
Unrealized gain on available-for-sale securities, net	—	—	—	2,163	—	2,163
Net loss	—	—	—	—	(116,319)	(116,319)
Balances at June 30, 2024	<u>49,317</u>	<u>\$ 5</u>	<u>\$ 1,171,894</u>	<u>\$ (2,266)</u>	<u>\$ (821,366)</u>	<u>\$ 348,267</u>
	Six Months Ended June 30, 2023					
	Common Stock		Additional Paid-in Capital	Accumulated		Total Stockholders'
				Other Comprehensive Loss	Accumulated Deficit	
	Shares	Amount	Capital	Loss	Deficit	Equity
Balances at December 31, 2022	43,299	\$ 4	\$ 973,145	\$ (15,401)	\$ (441,553)	\$ 516,195
Vesting of restricted stock units, net of tax	127	—	(419)	—	—	(419)
Exercise of stock options, net of tax	165	—	1,220	—	—	1,220

Issuance of common stock under employee stock purchase plan	30	—	583	—	—	583
Stock-based compensation expense	—	—	21,710	—	—	21,710
Unrealized gain on available-for-sale securities, net	—	—	—	5,303	—	5,303
Net loss	—	—	—	—	(138,737)	(138,737)
Balances at June 30, 2023	43,621	\$ 4	\$ 996,239	\$ (10,098)	\$ (580,290)	\$ 405,855

The accompanying notes are an integral part of these unaudited consolidated financial statements.

[Table of Contents](#)

REGENXBIO INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)

	Three Months Ended March 31,		Six Months Ended June 30,	
	2024	2023	2024	2023
Cash flows from operating activities				
Net loss	\$ (63,330)	\$ (66,676)	\$ (116,319)	\$ (138,737)
Adjustments to reconcile net loss to net cash used in operating activities				
Stock-based compensation expense	9,602	11,206	19,037	21,710
Depreciation and amortization	4,180	4,178	8,231	8,613
Net amortization of premiums (accretion of discounts) on marketable debt securities	(468)	682	(1,711)	1,062
Impairment of long-lived assets	2,101	—	2,101	—
Non-cash interest expense	688	(574)	(27)	(1,236)
Other non-cash adjustments	(71)	(122)	(71)	(165)
Changes in operating assets and liabilities				
Accounts receivable	9,177	9,495	2,284	7,108
Prepaid expenses	930	(1,621)	4,499	(1,212)
Other current assets	(6,826)	(13,651)	(2,970)	(12,846)
Operating lease right-of-use assets	1,528	1,390	3,011	2,806
Other assets	590	(1,893)	1,861	2,564
Accounts payable	8,461	(3,103)	(6,454)	(14,108)
Accrued expenses and other current liabilities	(17,077)	(15,443)	(7,551)	3,501
Deferred revenue	(135)	(433)	(127)	(1,212)
Operating lease liabilities	(2,041)	(1,504)	(4,023)	(3,345)
Other liabilities	(2,764)	(2,849)	(2,723)	(2,743)
Net cash used in operating activities	(55,455)	(80,918)	(100,952)	(128,240)
Cash flows from investing activities				

Purchases of marketable debt securities	(55,190)	—	(137,718)	(49,795)
Maturities of marketable debt securities	68,930	67,912	151,664	175,502
Purchases of property and equipment	(557)	(4,818)	(1,031)	(7,395)
Net cash provided by investing activities	13,183	63,094	12,915	118,312
Cash flows from financing activities				
Proceeds from exercise of stock options	884	471	1,076	1,220
Taxes paid related to net settlement of stock-based awards	(910)	(419)	(910)	(419)
Proceeds from issuance of common stock under employee stock purchase plan	411	583	411	583
Proceeds from public offering of common stock and pre-funded warrants, net of underwriting discounts and commissions	131,601	—	131,601	—
Issuance costs for public offering of common stock and pre-funded warrants	(249)	—		
Offering expenses related to at-the-market offering program	(35)	—	(138)	—
Repayments under liability related to sale of future royalties, net of imputed interest	(11,226)	(9,672)	(20,511)	(19,583)
Net cash provided by (used in) financing activities	120,725	(9,037)	111,280	(18,199)
Net increase (decrease) in cash and cash equivalents and restricted cash	78,453	(26,861)	23,243	(28,127)
Cash and cash equivalents and restricted cash				
Beginning of period	36,552	98,982	36,552	98,982
End of period	\$ 115,005	\$ 72,121	\$ 59,795	\$ 70,855

The accompanying notes are an integral part of these unaudited consolidated financial statements.

67

[Table of Contents](#)

REGENXBIO INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1. Nature of Business

REGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company's investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform (NAV Technology Platform). The NAV® Technology Platform consists of exclusive rights to a large portfolio of AAV vectors, including commonly used AAV8 and AAV9. The Company has developed a broad pipeline of gene therapy product candidates using the NAV Technology Platform as a one-time treatment to address an array of diseases. In addition to its internal product development efforts, the Company also selectively licenses the NAV Technology Platform to other leading biotechnology and pharmaceutical companies (NAV Technology Licensees). As of **March 31, 2024** **June 30, 2024**, the NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma®, and in the preclinical and clinical development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development and commercialization of certain product candidates. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.

The Company has incurred cumulative losses since inception and as of **March 31, 2024** **June 30, 2024**, had generated an accumulated deficit of **\$768.4** **821.4** million. The Company's ability to transition to recurring profitability is dependent upon achieving a level of revenues adequate to support its cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, the Company will continue to need to raise additional capital. There is no assurance that the Company will be able to raise sufficient capital or obtain financing on favorable terms, or at all. As of **March 31, 2024** **June 30, 2024**, the Company had cash, cash equivalents and marketable securities of **\$380.5** **327.3** million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024. Certain information and footnote disclosures required by GAAP, which are normally included in the Company's annual consolidated financial statements, have been omitted pursuant to SEC rules and regulations for interim reporting. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for **a fair financial statement presentation. of the results of operations for the periods presented.**

The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year, any other interim periods, or any future year or period. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements.

Reclassifications

Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.

Restricted Cash

Restricted cash consists of deposits held at financial institutions that are used to collateralize irrevocable letters of credit required under the Company's lease agreements and certain other agreements with third parties. The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):

	As of March 31,		As of June 30,	
	2024	2023	2024	2023
Cash and cash equivalents	\$ 112,975	\$ 70,091	\$ 57,765	\$ 68,600
Restricted cash	2,030	2,030	2,030	2,255
Total cash and cash equivalents and restricted cash	\$ 115,005	\$ 72,121	\$ 59,795	\$ 70,855

Accounts Receivable

Accounts receivable primarily consist of consideration due to the Company resulting from its license agreements with customers. Accounts receivable include amounts invoiced to licensees as well as rights to consideration which have not yet been invoiced, including unbilled royalties, and for which payment is conditional solely upon the passage of time. If a licensee elects to terminate a license prior to the end of the license term, the licensed intellectual property is returned to the Company and any accounts receivable from the licensee which are not contractually payable to the Company are charged off as a reduction of license revenue in the period of the termination. Accounts receivable which are not expected to be received by the Company within 12 months from the reporting date are stated net of a discount to present value and recorded as non-current assets on the consolidated balance sheets. The present value discount is recognized as a reduction of revenue in the period in which the accounts receivable are initially recorded and is accreted as interest income from licensing over the term of the receivables.

Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company's evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances, and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company's evaluation of current and expected future economic conditions. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Please refer to Note 9 for further information regarding the allowance for credit losses related to accounts receivable.

Leases

The Company accounts for its lease arrangements in accordance with Accounting Standards Codification (ASC) 842, *Leases* (ASC 842). Under ASC 842, the Company classifies its leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the Company. Lease classification is evaluated at the inception of the lease agreement. Regardless of classification, the Company records a right-of-use asset and a lease liability for all leases with a term greater than 12 months. All of the Company's leases have been classified as operating leases. Operating lease expense is recognized on a straight-line basis over the term of the lease, with the exception of variable lease expenses which are recognized as incurred.

The Company identifies leases in its contracts if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company does not allocate lease consideration between lease and nonlease components and records a lease liability equal to the present value of the remaining fixed consideration under the lease. The interest rates implicit in the Company's leases are generally not readily determinable. Accordingly, the Company uses its estimated incremental borrowing rate at the commencement date of the lease to determine the present value discount of the lease liability. The Company estimates its incremental borrowing rate for each lease based on an evaluation of its expected credit rating and the prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the term of the lease. The right-of-use asset for each lease is equal to the lease liability, adjusted for unamortized initial direct

costs and lease incentives and prepaid or accrued rent. Initial direct costs of entering into a lease are included in the right-of-use asset and amortized as lease expense over the term of the lease. Lease incentives, such as tenant improvement allowances, are recorded as a

9

[Table of Contents](#)

reduction of the right-of-use asset and amortized as a reduction of lease expense over the term of the lease. The Company excludes options to extend or terminate leases from the calculation of the lease liability unless it is reasonably certain the option will be exercised.

8

[Table of Contents](#)

The Company evaluates its right-of-use assets for impairment in accordance with its policy for long-lived assets. To the extent an impairment of a right-of-use asset is recognized, the remaining carrying value of the asset is subsequently amortized as lease expense on a straight-line basis from the date of impairment to the earlier of the end of the right-of-use asset's useful life or the end of the lease term.

The Company determines the classification of subleases at the inception of the sublease, as well as whether the Company has been relieved of its primary obligation under the original lease. All of the Company's subleases have been classified as operating leases and, in each case, the Company has not been relieved of its primary obligation under the original lease and continues to account for the original lease as it did prior to the commencement of the sublease. Sublease income is recognized on a straight-line basis over the term of the sublease as a reduction of the related lease expense of the original lease. Initial direct costs of entering into a sublease are deferred and amortized on a straight-line basis over the term of the sublease as a reduction of sublease income.

Impairment of Long-lived Assets

The Company's long-lived assets consist primarily of property and equipment and operating lease right-of-use assets. The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to estimated future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. Please refer to Note 5 and Note 6 for further information on impairment of long-lived assets.

Fair Value Measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, *Fair Value Measurements and Disclosures*, establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation

inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:

- Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
- Level 3—Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within the fair value hierarchy of an asset or liability measured at fair value is based on the lowest level of any input that is significant to the fair value measurement. The fair values of the Company's Level 2 financial instruments are based on quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Please refer to Note 4 for further information on the Company's fair value measurements.

10

[Table of Contents](#)

Pre-funded Warrants

Warrants are accounted for based on the specific terms of the warrant agreements. The Company's pre-funded warrants are indexed to the Company's common stock and meet the criteria to be classified as equity. Proceeds from the issuance of pre-funded warrants are recorded within additional paid-in capital and are not subject to remeasurement. Please refer to Note 8 for further information regarding pre-funded warrants issued by the Company.

9

[Table of Contents](#)

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of computing both basic and diluted net loss per share, pre-funded warrants are considered outstanding shares upon issuance because the shares may be issued for nominal consideration and are exercisable after the original issuance date. Contingently convertible shares in which conversion is based on non-market-priced contingencies are excluded from the calculations of both basic and diluted net loss per share until the contingency has been fully met. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation of diluted net loss per share if their effect would be anti-dilutive.

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

The Company did not adopt any new accounting standards during the three and six months ended **March 31, 2024**, **June 30, 2024** and 2023 which had a material impact on the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances certain interim and annual disclosure requirements of reportable segment information, including information about significant segment expenses. Additionally, the standard requires entities with a single reportable segment to provide all disclosures required by ASC 280, *Segment Reporting*. The standard is effective for the Company for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, with early adoption permitted. The Company does not believe the adoption of this standard will have a material impact on its financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which enhances the disclosure of an entity's effective tax rate reconciliation and requires the disclosure of income taxes paid to be disaggregated by jurisdiction. The standard is effective for the Company beginning January 1, 2025, with early adoption permitted. The Company does not believe the adoption of this standard will have a material impact on its financial statement disclosures.

3. Marketable Securities

The following tables present a summary of the Company's marketable securities, which consist solely of available-for-sale debt securities (in thousands):

	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
March 31, 2024								
June 30, 2024								
U.S. government and agency securities	\$ 87,801	\$ —	\$ (975)	\$ 86,826	\$ 84,611	\$ —	\$ (657)	\$ 83,954
Certificates of deposit	6,327	—	(78)	6,249	5,606	—	(48)	5,558
Corporate bonds	175,776	37	(1,353)	174,460	180,724	17	(718)	180,023
	<u>\$ 269,904</u>	<u>\$ 37</u>	<u>\$ (2,406)</u>	<u>\$ 267,535</u>	<u>\$ 270,941</u>	<u>\$ 17</u>	<u>\$ (1,423)</u>	<u>\$ 269,535</u>

11

[Table of Contents](#)

	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
December 31, 2023				
U.S. government and agency securities	\$ 71,811	\$ 6	\$ (1,248)	\$ 70,569
Certificates of deposit	6,572	—	(106)	6,466
Corporate bonds	204,793	143	(2,364)	202,572
	<u>\$ 283,176</u>	<u>\$ 149</u>	<u>\$ (3,718)</u>	<u>\$ 279,607</u>

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, no available-for-sale debt securities had remaining maturities greater than three years. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, or to the earliest call date for callable debt securities purchased at a premium.

10

Table of Contents

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, the balance in accumulated other comprehensive loss consisted solely of unrealized gains and losses on available-for-sale debt securities, net of reclassification adjustments for realized gains and losses and income tax effects. The Company uses the aggregate portfolio approach to release the tax effects of unrealized gains and losses on available-for-sale debt securities in accumulated other comprehensive loss. Realized gains and losses from the sale or maturity of marketable securities are based on the specific identification method and are included in results of operations as investment income. The Company did not recognize any realized gains or losses on available-for-sales securities during the three **and six** months ended **March 31, 2024** **June 30, 2024** and 2023, and no income tax effects or reclassification adjustments were recorded in accumulated other comprehensive loss during the periods.

The following tables present the fair values and unrealized losses of available-for-sale debt securities held by the Company in an unrealized loss position for less than 12 months and 12 months or greater (in thousands):

	Less than 12 Months		12 Months or Greater		Total		Less than 12 Months		12 Months or Greater		Total	
	Unrealized		Unrealized		Unrealized		Unrealized		Unrealized		Unrealized	
	Fair Value	Losses	Fair Value	Losses	Fair Value	Losses	Fair Value	Losses	Fair Value	Losses	Fair Value	Losses
March 31, 2024												
June 30, 2024												
U.S. government and agency securities	\$ 41,321	\$ (21)	\$ 45,505	\$ (954)	\$ 86,826	\$ (975)	\$ 45,623	\$ (14)	\$ 38,331	\$ (643)	\$ 83,954	\$ (657)
Certificates of deposit	722	(3)	5,282	(75)	6,004	(78)	489	(1)	4,825	(47)	5,314	(48)
Corporate bonds	48,933	(146)	92,795	(1,207)	141,728	(1,353)	107,667	(303)	48,486	(415)	156,153	(718)
	<u>\$ 90,976</u>	<u>\$ (170)</u>	<u>\$ 143,582</u>	<u>\$ (2,236)</u>	<u>\$ 234,558</u>	<u>\$ (2,406)</u>	<u>\$ 153,779</u>	<u>\$ (318)</u>	<u>\$ 91,642</u>	<u>\$ (1,105)</u>	<u>\$ 245,421</u>	<u>\$ (1,423)</u>

	Less than 12 Months		12 Months or Greater		Total	
	Unrealized		Unrealized		Unrealized	
	Fair Value	Losses	Fair Value	Losses	Fair Value	Losses
December 31, 2023						
U.S. government and agency securities	\$ 12,877	\$ (16)	\$ 52,686	\$ (1,232)	\$ 65,563	\$ (1,248)
Certificates of deposit	965	(2)	5,257	(104)	6,222	(106)

Corporate bonds	25,051	(48)	144,642	(2,316)	169,693	(2,364)
	<u>\$ 38,893</u>	<u>\$ (66)</u>	<u>\$ 202,585</u>	<u>\$ (3,652)</u>	<u>\$ 241,478</u>	<u>\$ (3,718)</u>

As of **March 31, 2024** **June 30, 2024**, available-for-sale debt securities held by the Company in an unrealized loss position consisted of **82** **80** investment grade security positions. The Company has the intent and ability to hold such securities until recovery, and based on the credit quality of the issuers and low severity of each unrealized loss position relative to its amortized cost basis, the Company did not identify any credit losses associated with its available-for-sale debt securities. The Company did not record an allowance for credit losses on its available-for-sale debt securities as of **March 31, 2024** **June 30, 2024** or December 31, 2023, and no impairment or credit losses on available-for-sale debt securities were recorded during the three and six months ended **March 31, 2024** **June 30, 2024** and 2023.

12

Table of Contents

4. Fair Value Measurements

Financial instruments reported at fair value on a recurring basis include cash equivalents and marketable securities. The following tables present the fair value of cash equivalents and marketable securities in accordance with the **fair value** hierarchy discussed in Note 2 (in thousands):

	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total	Level 1	Level 2	Level 3	Total
March 31, 2024								
June 30, 2024								
Cash equivalents:								
Money market mutual funds	\$ —	\$ 73,399	\$ —	\$ 73,399	\$ —	\$ 55,667	\$ —	\$ 55,667
Total cash equivalents	—	73,399	—	73,399	—	55,667	—	55,667
Marketable securities:								
U.S. government and agency securities	—	86,826	—	86,826	—	83,954	—	83,954
Certificates of deposit	—	6,249	—	6,249	—	5,558	—	5,558
Corporate bonds	—	174,460	—	174,460	—	180,023	—	180,023
Total marketable securities	—	267,535	—	267,535	—	269,535	—	269,535
Total cash equivalents and marketable securities	<u>\$ —</u>	<u>\$ 340,934</u>	<u>\$ —</u>	<u>\$ 340,934</u>	<u>\$ —</u>	<u>\$ 325,202</u>	<u>\$ —</u>	<u>\$ 325,202</u>

11

[Table of Contents](#)

	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total	Level 1	Level 2	Level 3	Total
December 31, 2023								
Cash equivalents:								
Money market mutual funds	\$ —	\$ 13,024	\$ —	\$ 13,024	\$ —	\$ 13,024	\$ —	\$ 13,024
Total cash equivalents	—	13,024	—	13,024	—	13,024	—	13,024
Marketable securities:								
U.S. government and agency securities	—	70,569	—	70,569	—	70,569	—	70,569
Certificates of deposit	—	6,466	—	6,466	—	6,466	—	6,466
Corporate bonds	—	202,572	—	202,572	—	202,572	—	202,572
Total marketable securities	—	279,607	—	279,607	—	279,607	—	279,607
Total cash equivalents and marketable securities	\$ —	\$ 292,631	\$ —	\$ 292,631	\$ —	\$ 292,631	\$ —	\$ 292,631

Management estimates that the carrying values of its current accounts receivable, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to the short-term nature of those instruments. Accounts receivable which contain non-current portions and certain non-current payables reported as other liabilities are recorded at their present values using a discount rate that is based on prevailing market rates on the date the amounts were initially recorded. Management does not believe there have been any significant changes in market conditions or credit quality that would cause the discount rates initially used to be materially different from those that would be used as of **March 31, 2024** **June 30, 2024** to determine the present value of these instruments. Accordingly, management estimates that the carrying values of its non-current accounts receivable and other liabilities approximate the fair value of those instruments. Management estimates that the carrying value of the liability related to the sale of future royalties approximates fair value. As discussed in Note 7, the carrying value of the liability related to the sale of future royalties is based on the Company's estimate of future royalties expected to be paid by the Company over the life of the arrangement, which are considered Level 3 inputs.

Long-lived assets, if determined to be not recoverable and impaired, are measured at fair value on a nonrecurring basis using Level 3 inputs. Please refer to Note 6 for further information on nonrecurring fair value measurements of long-lived assets during the three **and six** months ended **March 31, 2024** **June 30, 2024** and **2023**.

[Table of Contents](#)

5. Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Laboratory and manufacturing equipment	\$ 75,931	\$ 75,632	\$ 76,256	\$ 75,632

Computer equipment and software	4,727	4,700	4,753	4,700
Furniture and fixtures	7,018	7,052	7,024	7,052
Leasehold improvements	101,340	101,927	101,339	101,927
Total property and equipment	189,016	189,311	189,372	189,311
Accumulated depreciation and amortization	(61,354)	(57,208)	(65,403)	(57,208)
Property and equipment, net	\$ 127,662	\$ 132,103	\$ 123,969	\$ 132,103

In March 2024, the Company entered into an agreement to sublease its office facilities in New York, New York. In connection with the sublease, the Company recorded impairment of property and equipment of \$0.7 million during in the three months ended March 31, 2024 first quarter of 2024 related to furniture and fixtures and leasehold improvements located at the subleased facility. No material impairment losses on property and equipment were recorded during the three months ended June 30, 2024 and the three and six months ended June 30, 2023. Please refer to Note 6 for further information regarding the sublease agreement and associated impairment of long-lived assets.

6. Leases

New York Sublease

In May 2016, the Company entered into an operating lease for office space in New York, New York (the New York Lease), which has since been amended to include additional office space and extend the term of the lease. The lease term commenced in July 2016 and expires in April 2027.

12

[Table of Contents](#)

In March 2024, the Company entered into an agreement to sublease its office space under the New York Lease (the New York Sublease) to a third-party subtenant. The sublease term commenced in April 2024 and will expire in April 2027 concurrent with the expiration of the New York Lease. Monthly payments under the New York Sublease are expected to begin in mid-2024 and escalate annually in accordance with the sublease agreement. As of March 31, 2024 June 30, 2024, total undiscounted future minimum lease payments to be received by the Company over the term of the New York Sublease were \$1.5 million. NoThe Company recognized sublease income was recognized during the three months ended March 31, 2024 of \$0.1 million under the New York Sublease as during the sublease had not yet commenced, three and six months ended June 30, 2024.

The New York Sublease is classified as an operating lease and the Company was not relieved of its primary obligation under the New York Lease. The Company will continue continues to account for the New York Lease as it did prior to the commencement of the sublease.

As a result of the New York Sublease, the Company determined an impairment indicator was present as of March 31, 2024 related to the long-lived asset group subject to the sublease, which includes included the right-of-use asset under the New York Lease, leasehold improvements and other property and equipment allocable to the New York Sublease. The Company concluded the carrying value of the asset group as of March 31, 2024 was not recoverable, as it exceeded the sum of the estimated undiscounted cash flows to be generated by the assets over their remaining lives. The Company estimated the fair value of the asset group as of March 31, 2024 using a discounted cash flow method, which incorporated unobservable inputs including the net identifiable cash flows over the term of the New York Sublease and an estimated borrowing rate of a market participant subtenant. The estimated fair value of the asset group as of March 31, 2024 represents a Level 3 nonrecurring fair value measurement. The Company concluded the carrying value of the asset group of \$3.4 million exceeded its estimated fair value of \$1.3 million as of March 31, 2024. TheAs such, the Company recognized impairment losses of \$2.1 million during the three months ended March 31, 2024 on the long-lived asset group associated with the New York Sublease. The impairment losses were allocated to the various assets within the long-lived asset group based on their relative carrying values as follows (in thousands): and consisted of \$1.4 million recorded to the right-of-use assets and \$0.7 million recorded to property and equipment. No material impairment losses on long-lived assets were recorded during the three months ended June 30, 2024 and the three and six months ended June 30, 2023.

[Table of Contents](#)

	Impairment Losses
March 31, 2024	
Property and equipment, net	\$ 700
Operating lease right-of-use assets	1,401
Total impairment of long-lived assets	\$ 2,101

7. Liability Related to Sale of Future Royalties

In December 2020, the Company entered into a royalty purchase agreement (the Royalty Purchase Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Under the Royalty Purchase Agreement, HCR purchased the Company's rights to a capped amount of Zolgensma royalty payments under the Company's license agreement (the Novartis License) with Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies), including \$4.0 million of royalty payments received by the Company in the fourth quarter of 2020 (the Pledged Royalties). In consideration for these rights, HCR paid the Company \$200.0 million (the Purchase Price), less \$4.0 million representing the payment of the Pledged Royalties to HCR. Beginning upon the effective date of the Royalty Purchase Agreement, Zolgensma royalty payments, up to a specified threshold, shall be paid to HCR, net of upstream royalties payable by the Company to certain licensors in accordance with existing license agreements.

Pursuant to the Royalty Purchase Agreement, the total amount of royalty payments to be received by HCR is subject to an increasing cap (the Cap Amount) equal to (i) \$260.0 million applicable for the period from the effective date of the Royalty Purchase Agreement through November 7, 2024, and (ii) \$300.0 million applicable for the period from November 8, 2024 through the effective date of termination of the Novartis License. If, on or prior to the defined dates for each Cap Amount, the total amount of royalty payments received by HCR equals or exceeds the Cap Amount applicable to such date, the Royalty Purchase Agreement will automatically terminate and all rights to the Zolgensma royalty payments will revert back to the Company. The Company has no obligation to repay any amounts to HCR if total future Zolgensma royalty payments are not sufficient to achieve the applicable Cap Amount prior to the termination of the Novartis License.

The Company has a call option to repurchase its rights to the purchased royalties from HCR for a repurchase price equal to, as of the option exercise date, \$300.0 million minus the total amount of royalty payments received by HCR; provided, however, that with respect to a call option exercised on or before November 7, 2024, in the event that the then applicable Cap Amount minus the total amount of royalty payments received by HCR is less than \$1.0 million, the repurchase price shall equal such difference.

The proceeds received from HCR of \$196.0 million were recorded as a liability, net of transaction costs of \$3.5 million, which is amortized over the estimated life of the arrangement using the effective interest method. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received by HCR, subject to the Cap Amount, over the life of the arrangement. The total amount of royalty payments received by HCR under the Royalty Purchase Agreement, less the net proceeds received by the Company of \$192.5 million, is recorded as interest expense over the life of the

[Table of Contents](#)

arrangement using the effective interest method. Due to its continuing involvement in the Novartis License, the Company continues to recognize royalty revenue on net sales of Zolgensma and records the royalty payments to HCR as a reduction of the liability when paid. As such payments are made to HCR, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement.

The Company estimates the effective interest rate used to record interest expense under the Royalty Purchase Agreement based on its estimate of future royalty payments to be received by HCR. As of **March 31, 2024** **June 30, 2024**, the estimated effective interest rate under the Royalty Purchase Agreement was **8.21.6%**. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the royalty payments received by HCR and changes in the Company's forecasted royalties. At each reporting date, the Company reassesses its estimate of total future royalty payments to be received by HCR at the applicable Cap Amount, and prospectively adjusts the effective interest rate and amortization of the liability, as necessary.

The following table presents the changes in the liability related to the sale of future royalties under the Royalty Purchase Agreement with HCR (in thousands):

	Liability Related to Sale of Future Royalties	Liability Related to Sale of Future Royalties
Balance at December 31, 2023	\$ 94,052	\$ 94,052
Zolgensma royalties paid to HCR	(12,511)	(22,959)
Interest expense recognized	1,776	2,086
Balance at March 31, 2024	83,317	
Balance at June 30, 2024	73,179	
Current portion of liability related to sale of future royalties	(38,615)	(32,100)
Liability related to sale of future royalties, non-current	\$ 44,702	\$ 41,079

[Table of Contents](#)

8. Capitalization

March 2024 Public Offering

In March 2024, the Company completed a public offering of 4,565,260 shares of its common stock at a price of \$23.00 per share and 1,521,740 pre-funded warrants to purchase shares of its common stock at a price of \$22.9999 per pre-funded warrant, which equaled the public offering price per share of the common stock less the \$0.0001 exercise price of each pre-funded warrant. The aggregate net proceeds received by the Company from the offering were \$131.1 million, net of underwriting discounts and commissions and offering expenses payable by the Company.

The rights and privileges of the pre-funded warrants issued under the March 2024 offering are set forth in the warrant agreement between the Company and each of the respective warrant holders. The pre-funded warrants are exercisable at the option of the warrant holder at any time and do not expire. However, as set forth in the warrant agreements with each holder, the number of pre-funded warrants that may be exercised at any given time may be limited if, upon exercise, the warrant holder and any of its affiliates would beneficially own more than 9.99% of the Company's common stock, or have

voting power of more than 9.99% of the Company's common stock. The limitation threshold may be increased or decreased by the warrant holder, with advance notice to the Company, to any other percentage not less than 4.99% nor in excess of 19.99%. Pre-funded warrants do not provide any of the rights or privileges provided by the Company's common stock, including any voting rights, until the pre-funded warrants are exercised and settled in underlying shares of common stock.

The Company evaluated the pre-funded warrants issued under the March 2024 offering and concluded the warrants are indexed to the Company's common stock, meet the criteria to be classified as equity and are not subject to remeasurement. The proceeds received from the issuance of the pre-funded warrants were recorded as additional paid-in capital. As of March 31, 2024, no pre-funded warrants had been exercised and there were 1,521,740 pre-funded warrants outstanding. In April 2024, the Company issued 197,000 shares of common stock upon the exercise of pre-funded warrants by one warrant holder, during the three and six months ended June 30, 2024. As of June 30, 2024, 1,324,740 pre-funded warrants remained outstanding.

At-the-Market Offering Program

In September 2023, the Company entered into an ATM Equity OfferingSM Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to \$150.0 million from time to time through BofA, acting as the Company's sales agent (the ATM Program). As of March 31, 2024 June 30, 2024, no shares of common stock had been sold under the ATM Program.

14

[Table of Contents](#)

9. License and Collaboration Agreements

License and Royalty Revenue

As of March 31, 2024 June 30, 2024, the Company's NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma, and in the development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development of certain product candidates. Consideration to the Company under its license agreements may include: (i) up-front and annual fees, (ii) milestone payments based on the achievement of certain development and sales-based milestones, (iii) sublicense fees, (iv) royalties on sales of licensed products and (v) other consideration payable upon optional goods and services purchased by licensees. Sublicense fees vary by license and range from a mid-single digit percentage to a low-double digit percentage of license fees received by licensees as a result of sublicenses. Royalties on net sales of commercialized products vary by license and range from a mid-single digit percentage to a low double-digit percentage of net sales by licensees.

License and royalty revenue consisted of the following (in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Zolgensma royalties	\$ 15,214	\$ 16,125	\$ 21,763	\$ 18,965	\$ 36,977	\$ 35,091
Other license and royalty revenue	408	3,013	532	1,012	940	4,024
Total license and royalty revenue	\$ 15,622	\$ 19,138	\$ 22,295	\$ 19,977	\$ 37,917	\$ 39,115

16

[Table of Contents](#)

Outstanding development milestone payments are evaluated each reporting period and are only included in the transaction price of each license and recognized as license revenue to the extent the milestones are considered probable of achievement. Sales-based milestones are excluded from the transaction price of each license agreement and recognized as royalty revenue in the period of achievement. As of **March 31, 2024** **June 30, 2024**, the Company's license agreements, excluding additional licenses that could be granted upon the exercise of options by licensees, contained unachieved milestones which could result in aggregate milestone payments to the Company of up to \$1.49 billion, including (i) \$523.9 million upon the commencement of various stages of clinical trials, (ii) \$109.8 million upon the submission of regulatory approval filings or upon regulatory approval of licensed products and (iii) \$855.0 million upon the achievement of specified sales targets for licensed products, including milestones payable upon the first commercial sale of licensed products. To the extent the milestone payments are realized by the Company, the Company may be obligated to pay sublicense fees to licensors based on a specified percentage of the fees earned by the Company. The achievement of these milestones is highly dependent on the successful development and commercialization of licensed products and it is at least reasonably possible that some or all of the milestone fees will not be realized by the Company.

Changes in Accounts Receivable, Contract Assets and Deferred Revenue

The following table presents the balances of the Company's net accounts receivable, contract assets and deferred revenue, as well as other information regarding revenue recognized during the periods presented (in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Accounts receivable, net, current and non-current:						
Beginning of period	\$ 25,491	\$ 29,586	\$ 16,351	\$ 20,161	\$ 25,491	\$ 29,586
End of period	\$ 16,351	\$ 20,161	\$ 23,273	\$ 22,523	\$ 23,273	\$ 22,523
Contract assets:						
Beginning of period	\$ —	\$ —	\$ —	\$ 2,000	\$ —	\$ —
End of period	\$ —	\$ 2,000	\$ 194	\$ 2,000	\$ 194	\$ 2,000
Deferred revenue:						
Beginning of period	\$ 148	\$ 1,829	\$ 13	\$ 1,311	\$ 148	\$ 1,829
End of period	\$ 13	\$ 1,311	\$ 21	\$ 448	\$ 21	\$ 448
Revenue recognized during the period from:						
Amounts included in deferred revenue at beginning of period	\$ 148	\$ 930	\$ 13	\$ 891	\$ 148	\$ 1,409
Performance obligations satisfied in previous periods	\$ 15,268	\$ 18,132	\$ 21,768	\$ 18,907	\$ 37,037	\$ 37,040

[Table of Contents](#)

As of **March 31, 2024** **June 30, 2024**, the Company had recorded deferred revenue of less than \$0.1 million which represents consideration received or unconditionally due from licensees for performance obligations that have not yet been satisfied by the Company. Unsatisfied performance obligations as

of **March 31, 2024** **June 30, 2024** consisted of research and development services to be performed by the Company related to licensed products, which will be satisfied as the services are performed. As of **March 31, 2024** **June 30, 2024**, the aggregate transaction price of the Company's license agreements allocated to performance obligations not yet satisfied, or partially satisfied, was \$ **0.9** **1.1** million, which is expected to be satisfied over a period of approximately **two years** **one year**.

Revenue recognized from performance obligations satisfied in previous periods, as presented in the table above, was primarily attributable to Zolgensma royalties and changes in the transaction prices of the Company's license agreements. Changes in transaction prices were primarily attributable to development milestones achieved or deemed probable of achievement during the periods which were previously not considered probable of achievement, resulting in a cumulative catch-up adjustment to revenue. Revenue recognized during the **three six** months ended **March 31, 2024** and **2023** **June 30, 2023** included **zero** and \$2.0 million respectively, in cumulative catch-up adjustments for changes in the probability of achievement of development milestones. **There were no cumulative catch-up adjustments to revenue for changes in the probability of achievement of development milestones during the three and six months ended June 30, 2024 or during the three months ended June 30, 2023.**

17

[Table of Contents](#)

Accounts Receivable, Contract Assets and the Allowance for Credit Losses

Accounts receivable, net consisted of the following (in thousands):

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Current accounts receivable:				
Billed to customers	\$ 101	\$ 265	\$ 261	\$ 265
Unbilled Zolgensma royalties	15,312	24,128	22,195	24,128
Due from Abeona, net of present value discount	4,702	4,587	4,821	4,587
Other unbilled	415	397	353	397
Allowance for credit losses	(4,702)	(4,587)	(4,821)	(4,587)
Current accounts receivable, net	15,828	24,790	22,809	24,790
Non-current accounts receivable:				
Other unbilled	523	701	464	701
Non-current accounts receivable, net	523	701	464	701
Total accounts receivable, net	\$ 16,351	\$ 25,491	\$ 23,273	\$ 25,491

The following table presents the changes in the allowance for credit losses related to accounts receivable and contract assets for the **three six** months ended **March 31, 2024** **June 30, 2024** (in thousands):

	Allowance for Credit Losses		Allowance for Credit Losses	
	Accounts Receivable	Contract Assets	Accounts Receivable	Contract Assets
Balance at December 31, 2023	\$ 4,587	\$ —	\$ 4,587	\$ —
Changes in present value discount of receivables	115	—	234	—
Balance at March 31, 2024	\$ 4,702	\$ —		
Balance at June 30, 2024	\$ 4,821	\$ —		

The Company's allowance for credit losses as of **March 31, 2024** **June 30, 2024** and December 31, 2023 was related solely to accounts receivable from Abeona Therapeutics Inc. (Abeona). Please refer to the section below, "Settlement Agreement with Abeona Therapeutics", for further information regarding amounts due from Abeona and the associated allowance for credit losses. The Company did not record a provision for credit losses for the three and six months ended **March 31, 2024** **June 30, 2024** and 2023.

Zolgensma License with Novartis Gene Therapies

In March 2014, the Company entered into an exclusive license agreement (as amended, the Novartis License) with Novartis Gene Therapies. Under the Novartis License, the Company granted Novartis Gene Therapies an exclusive, worldwide commercial license, with rights to sublicense, to the NAV Technology Platform, as well as other certain rights, for the treatment of spinal muscular atrophy (SMA) in humans by *in vivo* gene therapy. In 2019, Novartis Gene Therapies launched commercial sales of Zolgensma, a licensed product under the Novartis License. In accordance with the Novartis License, the Company receives royalties on net sales of Zolgensma.

16

[Table of Contents](#)

The Company recognized the following amounts under the Novartis License (in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Zolgensma royalties	\$ 15,214	\$ 16,125	\$ 21,763	\$ 18,965	\$ 36,977	\$ 35,091
Total license and royalty revenue	\$ 15,214	\$ 16,125	\$ 21,763	\$ 18,965	\$ 36,977	\$ 35,091
Interest income from licensing	\$ 7	\$ 8	\$ 6	\$ 7	\$ 13	\$ 15

18

[Table of Contents](#)

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, the Company had recorded total accounts receivable of **\$15.5** **22.4** million and \$24.3 million, respectively, from Novartis Gene Therapies under the Novartis License, which consisted primarily of Zolgensma royalties receivable. The Zolgensma royalties receivable recorded as of **March 31, 2024** **June 30, 2024** included **\$11.0** **11.7** million expected to be paid to HCR in accordance with the Royalty Purchase Agreement discussed in Note 7. The Company recognizes royalty revenue from net sales of Zolgensma in the period in which the underlying products are sold by Novartis Gene Therapies, which in certain cases may require the Company to estimate royalty revenue for periods of net sales which have not yet been reported to the Company. Estimated royalties are reconciled to actual amounts reported in subsequent periods, and any differences are recognized as an adjustment to royalty revenue in the period the royalties are reported.

Settlement Agreement with Abeona Therapeutics

In November 2021, the Company entered into a settlement agreement and mutual release with Abeona (the Settlement Agreement) related to claims associated with a license agreement between the parties which was terminated in May 2020. The Settlement Agreement resolved all arbitration and legal proceedings and mutually released each party from any and all claims under the terminated license agreement. Pursuant to the Settlement

Agreement, Abeona will pay the Company a total of \$30.0 million as follows: (i) \$20.0 million which was paid in November 2021, (ii) \$5.0 million which was paid in November 2022, and (iii) \$5.0 million payable on the earlier of the third anniversary of the Settlement Agreement in November 2024 or the closing of a specified type of transaction by Abeona.

As of **March 31, 2024** **June 30, 2024** and December 31, 2023, the Company had recorded accounts receivable of **\$4.7** **4.8** million and \$4.6 million, respectively, associated with the remaining amounts due from Abeona under the Settlement Agreement. The receivable of **\$4.7** **4.8** million as of **March 31, 2024** **June 30, 2024** consisted of the \$5.0 million payment due by November 2024, net of discount to present value. While the Company anticipates taking appropriate measures to enforce the full collection of all amounts due from Abeona under the Settlement Agreement, the Company assessed the collectability of the accounts receivable from Abeona as it relates to credit risk. In performing this assessment, the Company evaluated Abeona's credit profile and financial condition, as well its expectations regarding Abeona's future cash flows and ability to satisfy the contractual obligations of the Settlement Agreement. As a result of its analysis, the Company recorded an allowance for credit losses of **\$4.7** **4.8** million and \$4.6 million as of **March 31, 2024** **June 30, 2024** and December 31, 2023, respectively, related to the accounts receivable due from Abeona. No credit losses or recoveries were recorded on the Abeona receivable during the three **and six** months ended **March 31, 2024** **June 30, 2024** and 2023. The present value discount of the Abeona receivable is accreted as interest income from licensing through the contractual due date using the effective interest method. The Company has elected to record increases in the allowance for credit losses associated with the accretion of the present value discount as a reduction of the associated interest income, resulting in no interest income recognized during the periods related to the accretion of the present value discount on the Abeona receivable.

Collaboration Agreements

AbbVie Collaboration and License Agreement

In September 2021, the Company entered into a collaboration and license agreement with AbbVie Global Enterprises Ltd. (AbbVie), a subsidiary of AbbVie Inc., to jointly develop and commercialize ABBV-RGX-314, the Company's product candidate for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases (the AbbVie Collaboration Agreement). **The AbbVie Collaboration Agreement became effective in November 2021.**

Pursuant to the AbbVie Collaboration Agreement, the Company granted AbbVie a co-exclusive license to develop and commercialize ABBV-RGX-314 in the United States and an exclusive license to develop and commercialize ABBV-RGX-314 outside the United States. The Company and AbbVie will collaborate to develop ABBV-RGX-314 in the United States, and AbbVie will be responsible for the development of ABBV-RGX-314 in specified markets outside the United States. Through December 31, 2022, the Company was responsible for the development expenses related to certain ongoing clinical trials of ABBV-RGX-314 and the parties shared the additional development expenses related to ABBV-RGX-314. Beginning on January 1, 2023, AbbVie became responsible for the majority of all ABBV-RGX-314 development expenses.

17 **19**

[Table of Contents](#)

The Company will lead the manufacturing of ABBV-RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead the manufacturing of ABBV-RGX-314 for commercial supply outside the United States. Manufacturing expenses will be allocated between the parties in accordance with the terms of the AbbVie Collaboration Agreement and supply agreements determined in accordance with the agreement. If requested by AbbVie, the Company will manufacture up to a specified portion of ABBV-RGX-314 for commercial supply outside the United States at a price specified in the agreement. AbbVie will lead the commercialization of ABBV-RGX-314 globally, and the Company will participate in U.S. commercialization efforts as provided under a commercialization plan determined in accordance with the agreement. The Company and AbbVie will share equally in the net profits and net losses associated with the commercialization of ABBV-RGX-314 in the United States. Outside the United States, AbbVie will be responsible, at its sole cost, for the commercialization of ABBV-RGX-314.

In consideration for the rights granted under the AbbVie Collaboration Agreement, AbbVie paid the Company an up-front fee of \$370.0 million upon the effective date of the agreement in November 2021 and is required to pay to the Company up to \$1.38 billion upon the achievement of specified development and sales-based milestones, of which \$562.5 million are based on development milestones and \$820.0 million are sales-based milestones. AbbVie is also required to pay to the Company tiered royalties on net sales of ABBV-RGX-314 outside the United States at percentages in the mid-teens to low twenties, subject to specified offsets and reductions.

The Company applied the requirements of ASC 606, *Revenue from Contracts with Customers* (ASC 606) to the AbbVie Collaboration Agreement for the units of account in which AbbVie was deemed to be a customer. The Company determined that there is only one material performance obligation under the agreement for the delivery of the intellectual property license to develop and commercialize ABBV-RGX-314 globally. The intellectual property licensed to AbbVie includes the rights to certain patents, data, know-how and other rights developed and owned by the Company, as well as other intellectual property rights exclusively licensed by the Company from various third parties. As of March 31, 2024, June 30, 2024 and December 31, 2023, the transaction price of the AbbVie Collaboration Agreement was \$370.0 million, which consisted solely of the up-front payment received from AbbVie in November 2021. The \$370.0 million transaction price was fully recognized as revenue upon the delivery of the license to AbbVie in November 2021. Variable consideration under the AbbVie Collaboration Agreement, which has been excluded from the transaction price, includes \$562.5 million in payments for development milestones that have not yet been achieved and were not considered probable of achievement. Additionally, the transaction price excludes sales-based milestone payments of \$820.0 million and royalties on net sales of ABBV-RGX-314 outside the United States. Development milestones will be added to the transaction price and recognized as revenue upon achievement, or if deemed probable of achievement. In accordance with the sale- or usage-based royalty exception under ASC 606, royalties on net sales and sales-based milestones will be recognized as revenue in the period the underlying sales occur or milestones are achieved. There were no changes in the transaction price of the AbbVie Collaboration Agreement, and no revenue was recognized, during the three and six months ended March 31, 2024, June 30, 2024 and 2023.

The Company applied the requirements of ASC 808, *Collaborative Arrangements* (ASC 808) to the AbbVie Collaboration Agreement for the units of account which were deemed to be a collaborative arrangement. Both the Company and AbbVie will perform various activities related to the development, manufacturing and commercialization of ABBV-RGX-314 in the United States. Development costs are shared between the parties in accordance with the terms of the AbbVie Collaboration Agreement, and the parties will share equally in the net profits and losses derived from sales of ABBV-RGX-314 in the United States. The Company accounts for payments to and from AbbVie for the sharing of development and commercialization costs in accordance with its accounting policy for collaborative arrangements. Amounts owed to AbbVie for the Company's share of development costs or commercialization costs incurred by AbbVie are recorded as research and development expense or general and administrative expense, respectively, in the period the costs are incurred. Amounts owed to the Company for AbbVie's share of development costs or commercialization costs incurred by the Company are recorded as a reduction of research and development expense or general and administrative expense, respectively, in the period the costs are incurred. At the end of each reporting period, the Company records a net amount due to or from AbbVie as a result of the cost-sharing arrangement. As of March 31, 2024, June 30, 2024 and December 31, 2023, the Company had recorded \$24.5, \$20.9 million and \$17.7 million, respectively, due from AbbVie for net reimbursement of costs incurred for activities performed under AbbVie Collaboration Agreement, which was included in other current assets on the consolidated balance sheets.

Table of Contents

The Company recognized the following amounts under the AbbVie Collaboration Agreement (in thousands):

	Three Months Ended March 31,	
	2024	2023
Net cost reimbursement to (from) AbbVie included in:		
Research and development expense	\$ (24,977)	\$ (18,474)

General and administrative expense	402	142
Total net cost reimbursement to (from) AbbVie	\$ (24,575)	\$ (18,332)

18

Table of Contents

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Net cost reimbursement to (from) AbbVie included in:				
Research and development expense	\$ (21,271)	\$ (18,218)	\$ (46,248)	\$ (36,692)
General and administrative expense	425	251	827	392
Total net cost reimbursement to (from) AbbVie	\$ (20,846)	\$ (17,967)	\$ (45,421)	\$ (36,300)

10. Stock-based Compensation

Effective in January 2024, an additional 1,761,849 shares were authorized for issuance under the 2015 Equity Incentive Plan (the 2015 Plan). As of **March 31, 2024** **June 30, 2024**, the total number of shares of common stock authorized for issuance under the 2015 Plan and the 2014 Stock Plan (the 2014 Plan) was 19,118,989, of which **2,532,031** **2,396,890** remained available for future grants under the 2015 Plan.

Stock-based Compensation Expense

The Company's stock-based compensation expense by award type was as follows (in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Stock options	\$ 5,978	\$ 8,177	\$ 5,940	\$ 7,416	\$ 11,918	\$ 15,594
Restricted stock units	3,447	2,781	3,334	2,852	6,781	5,632
Employee stock purchase plan	177	248	161	236	338	484
	\$ 9,602	\$ 11,206	\$ 9,435	\$ 10,504	\$ 19,037	\$ 21,710

As of **March 31, 2024** **June 30, 2024**, the Company had **\$78.8** **70.2** million of unrecognized stock-based compensation expense related to stock options, restricted stock units and the 2015 Employee Stock Purchase Plan (the 2015 ESPP), which is expected to be recognized over a weighted-average period of **2.7** **2.5** years.

The Company recorded aggregate stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Research and development	\$ 4,893	\$ 6,070	\$ 4,699	\$ 5,470	\$ 9,592	\$ 11,540
General and administrative	4,709	5,136	4,736	5,034	9,445	10,170
	\$ 9,602	\$ 11,206	\$ 9,435	\$ 10,504	\$ 19,037	\$ 21,710

[Table of Contents](#)
Stock Options

The following table summarizes stock option activity under the 2014 Plan and 2015 Plan (in thousands, except per share data):

	2014 Plan				2015 Plan			
	Shares	Weighted-average Exercise Price	Weighted-average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (a)	Shares	Weighted-average Exercise Price	Weighted-average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (a)
Outstanding at December 31, 2023	8,581	\$ 32.62	6.2	\$ 7,011	8,581	\$ 32.62	6.2	\$ 7,011
Granted	1,446	\$ 18.31			1,666	\$ 17.80		
Exercised	(135)	\$ 6.57			(173)	\$ 6.21		
Cancelled or forfeited	(333)	\$ 39.37			(436)	\$ 36.56		
Outstanding at March 31, 2024	9,559	\$ 30.59	6.5	\$ 12,557				
Exercisable at March 31, 2024	6,317	\$ 34.15	5.3	\$ 8,374				
Vested and expected to vest at March 31, 2024	9,559	\$ 30.59	6.5	\$ 12,557				
Outstanding at June 30, 2024	9,638	\$ 30.36	6.3	\$ 1,522				
Exercisable at June 30, 2024	6,525	\$ 34.12	5.2	\$ 1,522				
Vested and expected to vest at June 30, 2024	9,638	\$ 30.36	6.3	\$ 1,522				

(a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at the dates reported.

The weighted-average grant date fair value per share of options granted during the three six months ended March 31, 2024 June 30, 2024 was \$11.41 11.04. During the three six months ended March 31, 2024 June 30, 2024, the total number of stock options exercised was 134,544 173,337, resulting in total proceeds of \$0.9 1.1 million. The total intrinsic value of options exercised during the three six months ended March 31, 2024 June 30, 2024 was \$1.6 2.0 million.

[Table of Contents](#)
Restricted Stock Units

The following table summarizes restricted stock unit activity under the 2015 Plan (in thousands, except per share data):

	Weighted-average		Weighted-average	
	Shares	Grant Date	Shares	Grant Date
		Fair Value		Fair Value
Unvested balance at December 31, 2023	1,309	\$ 25.89	1,309	\$ 25.89
Granted	720	\$ 18.30	773	\$ 18.05
Vested	(321)	\$ 27.84	(358)	\$ 27.12
Forfeited	(20)	\$ 22.51	(56)	\$ 22.77
Unvested balance at March 31, 2024	1,688	\$ 22.32		
Unvested balance at June 30, 2024	1,668	\$ 22.10		

The total intrinsic value of restricted stock units vested during the **three** **six** months ended **March 31, 2024** **June 30, 2024** was **\$5.7** **6.3** million.

Employee Stock Purchase Plan

As of **March 31, 2024** **June 30, 2024**, the total number of shares of common stock authorized for issuance under the 2015 ESPP was 1,426,994, of which 991,402 remained available for future issuance. During the **three** **six** months ended **March 31, 2024** **June 30, 2024**, 26,962 shares of common stock were issued under the 2015 ESPP.

11. Income Taxes

The Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets as of **March 31, 2024** **June 30, 2024** and December 31, 2023. Based on the Company's history of operating losses, and other relevant facts and circumstances, the Company concluded that it was more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company provided a full valuation allowance for its net deferred tax assets as of **March 31, 2024** **June 30, 2024** and December 31, 2023.

22

[Table of Contents](#)

12. Restructuring

In November 2023, the Company implemented a strategic pipeline prioritization and corporate restructuring designed to reduce operating expenses and prioritize the development of ABBV-RGX-314, RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), while pursuing strategic alternatives for the Company's other clinical stage programs. The restructuring included a reduction in workforce and other planned operating expenses, primarily in rare neurodegenerative disease development, early research and other general and administrative areas.

As a result of the restructuring, the Company implemented a reduction in workforce of approximately 15%, which was substantially completed in the fourth quarter of 2023. The Company recorded restructuring costs of \$3.7 million in the fourth quarter of 2023, which primarily consisted of employee severance, continuing healthcare benefits and other employee-related costs. During the **three** **six** months ended **March 31, 2024** **June 30, 2024**, the Company recorded reductions in the restructuring liability of **\$0.3** **0.4** million associated with changes in total estimated restructuring costs. The Company expects cash payments related to the restructuring costs to be completed by the **third quarter** **end** of 2024.

The following table presents the details of the Company's restructuring liability, which is included in accrued expenses and other current liabilities on the consolidated balance sheet as of **March 31, 2024** **June 30, 2024** (in thousands):

	Restructuring Liability	Restructuring Liability
Balance at December 31, 2022	\$ —	\$ —
Restructuring charges	3,731	3,731
Cash payments	(1,925)	(1,925)
Balance at December 31, 2023	1,806	1,806
Cash payments	(1,197)	(1,367)
Other adjustments	(333)	(428)
Balance at March 31, 2024	\$ 276	
Balance at June 30, 2024	\$ 11	

[Table of Contents](#)

13. Net Loss Per Share

Since the Company incurred net losses for the three and six months ended March 31, 2024, June 30, 2024 and 2023, common stock equivalents were excluded from the calculation of diluted net loss per share for such periods as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share were the same for such periods. The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of 1,521,740 outstanding pre-funded warrants to purchase shares of the Company's common stock, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands):

	Three Months Ended March 31,		Three and Six Months Ended June 30,	
	2024	2023	2024	2023
Stock options issued and outstanding	9,559	8,996	9,638	8,905
Unvested restricted stock units outstanding	1,688	1,415	1,668	1,424
Employee stock purchase plan	45	58	78	73
	11,292	10,469	11,384	10,402

14. Supplemental Disclosures

Other Current Assets

Other current assets consisted of the following (in thousands):

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Net cost reimbursement due from collaborators	\$ 24,526	\$ 17,745	\$ 20,922	\$ 17,745
Accrued interest on investments	1,498	1,551	1,387	1,551
Other	1,273	1,107	1,187	1,107
	\$ 27,297	\$ 20,403	\$ 23,496	\$ 20,403

[Table of Contents](#)

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	March 31, 2024	December 31, 2023	June 30, 2024	December 31, 2023
Accrued external research and development expenses	\$ 14,508	\$ 13,762	\$ 14,350	\$ 13,762
Accrued sublicense fees and royalties	13,060	14,234		
Accrued personnel costs	8,085	18,146	12,449	18,146
Accrued sublicense fees and royalties	6,862	14,234		
Accrued external general and administrative expenses	2,532	2,717	1,901	2,717
Accrued purchases of property and equipment	149	386	137	386
Other accrued expenses and current liabilities	993	458	591	458
	<u>\$ 33,129</u>	<u>\$ 49,703</u>	<u>\$ 42,488</u>	<u>\$ 49,703</u>

Supplemental Disclosures of Non-cash Investing and Financing Activities

Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities were \$0.20.1 million as of March 31, 2024 June 30, 2024, a net decrease of \$0.20.3 million from December 31, 2023, and \$1.80.8 million as of March 31, 2023 June 30, 2023, a net decrease of \$0.81.8 million from December 31, 2022.

Issuance costs for the public offering of common stock and pre-funded warrants included in accounts payable and accrued expenses and other liabilities as of March 31, 2024 June 30, 2024 were \$0.50.3 million. No such amounts were recorded as of March 31, 2023 June 30, 2023.

Offering expenses for the ATM Program included in accounts payable and accrued expenses and other liabilities as of March 31, 2024 June 30, 2024 were less than \$0.1 million. No such amounts were recorded as of March 31, 2023 June 30, 2023.

21 24

[Table of Contents](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which we filed with the SEC on February 27, 2024. In addition, you should read the "Risk Factors" and "Information Regarding Forward-Looking Statements" sections of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects.

Overview of Product Candidates

We have developed a broad pipeline of gene therapy programs using our proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) as a one-time treatment to address an array of diseases. Our lead programs and product candidates are described below:

- **ABBV-RGX-314:** We are developing ABBV-RGX-314 in collaboration with AbbVie as a potential one-time treatment for chronic retinal conditions which cause total or partial vision loss, including wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other additional chronic retinal conditions which cause total or partial vision loss, diabetic macular edema (DME). ABBV-RGX-314 is currently being evaluated in multiple ongoing clinical trials, including two pivotal trials (ATMOSPHERE and ASCENT), one Phase II bridging study, one Long-term Follow-up study, and a Fellow Eye Treatment study in patients with wet AMD, all utilizing subretinal delivery. Additionally, two Phase II clinical trials in patients with wet AMD (AAVIATE) and DR and DME (ALTITUDE) are also ongoing along with two corresponding Long-term Follow-up studies, all utilizing in-office suprachoroidal delivery. ABBV-RGX-314 uses the NAV[®] AAV8 vector to deliver a gene encoding a therapeutic antibody fragment to inhibit vascular endothelial growth factor (VEGF). We have licensed certain exclusive rights to the SCS Microinjector[®] from Clearside Biomedical, Inc. (Clearside) to deliver gene therapy treatments to the suprachoroidal space of the eye.

Subretinal Delivery for Treatment of Wet AMD

Enrollment continues to be on track in the ATMOSPHERE[®] and ASCENT[™] pivotal trials for the treatment of patients with wet AMD using subretinal delivery. These trials are expected to support global regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the first half of 2026. The open label fellow eye study evaluating ABBV-RGX-314 in patients treated in the subretinal Phase I/IIa study is now fully enrolled. This study is designed to monitor safety, immune responses, and efficacy of ABBV-RGX-314 treatment in the fellow eye and these study data are intended to support the inclusion of bilateral use in the product label. Bilateral disease impacts a significant number of patients with wet AMD.

Suprachoroidal Delivery for Treatment of Wet AMD

The AAVIATE[®] trial is a multi-center, open label, randomized, controlled, dose-escalation Phase II trial to evaluate the efficacy, safety and tolerability of suprachoroidal delivery of ABBV-RGX-314 for the treatment of wet AMD. In January 2024, we presented data from the trial demonstrating that, As of July 29, 2024, ABBV-RGX-314 at six months, patients treated with ABBV-RGX-314 continue to demonstrate stable vision and retinal anatomy while a meaningful reduction in anti-VEGF treatment burden was observed. The highest reduction was seen in dose level 3 demonstrating an 80% reduction with short course prophylactic steroid eye drops continues to be well tolerated with no drug-related serious adverse events (SAEs) and no cases of intraocular inflammation, endophthalmitis, vasculitis, retinal artery occlusion, choroidal effusion, or hypotony. Mild episcleritis occurred in annualized injection rate three patients, all resolved and completed treatment with 50% topical steroids. There were no cases of patients remaining injection-free. We expect to share new program and data updates for elevated intraocular pressure. Based on this favorable safety profile, the Phase II AAVIATE trial is initiating enrollment in the third quarter of 2024, a new cohort to evaluate ABBV-RGX-314 at dose level 4 (1.5x10¹² GC/eye). Patients in this cohort will also receive short course prophylactic steroid eye drops.

Suprachoroidal Delivery for Treatment of DR and DME

The ALTITUDE[®] trial is a multi-center, open label, randomized, controlled, dose-escalation Phase II trial to evaluate the efficacy, safety and tolerability of ABBV-RGX-314 for the treatment of DR. Based on positive interim results from the this

[Table of Contents](#)

trial to date, the design and evaluation of two pivotal trials is on-going and in support of further discussion on-going. With AbbVie, we have accelerated a planned End-of-Phase II (EOP2) meeting with the FDA, at an end-of-Phase II (EOP2) meeting anticipated now expected in the first fourth quarter of 2025 that can enable rapid acceleration towards pivotal development. We expect 2024. The Company expects to initiate the first global pivotal trial in the first half of 2025.

The ALTITUDE trial is now enrolling a new cohort of patients with center-involved DME. Patients will receive a one-time, in-office injection of ABBV-RGX-314 at dose level 4 (1.5x10¹² GC/eye) with short course prophylactic steroid eye drops. DME is a vision-threatening complication of DR; an estimated 34 million people globally have DME.

- **RGX-202:** We are developing RGX-202 as an investigational one-time AAV therapeutic for the treatment of Duchenne muscular dystrophy (Duchenne), using the NAV AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain as well as a muscle-specific promoter to support a targeted therapy for improved resistance to muscle damage associated with Duchenne.

[Table of Contents](#)

AFFINITY DUCHENNE® is a multicenter, open-label dose evaluation escalation and dose expansion clinical trial study to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne. Duchenne aged 1 to 11 years old. In March 2024 and May 2024, we reported additional interim safety and efficacy data from the trial, in patients ages 4 to 11 years old, including RGX-202 microdystrophin from dose level 2.

As of May 3, 2024, RGX-202 continues to be well tolerated in all expression for the first two patients with no serious adverse events. In new data from the second patient, aged 8.1 years, who received RGX-202 at dose level 2 (DL2).

In August 2024, we announced new data from two patients, aged 5.8 and 8.5 years, who received RGX-202 at DL2. RGX-202 microdystrophin expression in these patients was measured to be 20.9% 77.2% and 46.5%, respectively, compared to control at three months. As of July 8, 2024, RGX-202 has been well tolerated with no SAEs. Data from all seven patients who completed three-month trial assessments indicate meaningful increases in expression of RGX-202 microdystrophin and reduction from baseline in serum creatinine kinase (CK) levels, supporting evidence of 90% was observed at 10 weeks. Dose level 2 has been selected as the pivotal dose and the positive interim results enable rapid acceleration into pivotal development. We are now enrolling patients in an expedited dose level 2 expansion phase of the AFFINITY DUCHENNE trial accepted by the FDA, and recently dosed two additional boys aged 5.8 and 8.5 years old. clinical improvement. We expect to enroll up to a total of seven patients at complete enrollment in the pivotal dose through early third quarter 2024. An EOP2 meeting with the FDA DL2 expansion cohort in early third quarter 2024 is expected and have initiated enrollment in the cohort for boys aged 1 to support a final pivotal trial design. 3 years old. We plan to use RGX-202 microdystrophin expression as a surrogate endpoint likely to predict clinical benefit to support a Biologics License Application (BLA) filing using the accelerated approval pathway. Initiation of the pivotal trial is expected in late third quarter 2024 to early fourth quarter 2024. We also continue to expect remain on track to share initial strength and functional assessment data for both dose levels of the AFFINITY DUCHENNE trial in the second half of 2024.

We recently held a successful EOP2 meeting with the FDA and are moving forward with plans to initiate a pivotal trial in the fourth quarter of 2024. Discussions with the FDA continue to support use of microdystrophin as a surrogate endpoint reasonably likely to predict clinical benefit for accelerated approval. We expect to share the pivotal trial design in late third quarter to early fourth quarter 2024. RGX-202 is manufactured using our proprietary, high-yielding NAVXpress™ platform process. This suspension-based manufacturing process has

demonstrated scalability up to 2,000 liters with consistent yield and product purity. Our Manufacturing Innovation Center has the capacity and yields to produce up to 2,500 doses of RGX-202 per year to support future commercialization.

- **RGX-121:** We are developing RGX-121 as an investigational one-time AAV therapeutic for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, using the NAV AAV9 vector to deliver the gene that encodes the iduronate-2-sulfatase enzyme.

CAMPSIITE® is a Phase I/II/III multi-center, open-label trial to evaluate the efficacy, safety, tolerability and pharmacodynamics of RGX-121 in patients with MPS II aged 4 months up to 5 years old. We continue to follow patients in the trial, and in February 2024, we reported that the pivotal phase of the CAMPSIITE trial achieved its primary endpoint. We plan to use levels of cerebrospinal fluid Heparan sulfate D2S6 as a surrogate endpoint reasonably likely to predict clinical benefit for accelerated approval and we are completing remaining activities in order to support a BLA biologics license application (BLA) submission in 2024. We believe that RGX-121 is likely to be eligible for priority review, especially if no other gene therapy product for MPS II is approved before submission of a BLA for RGX-121, and potential approval of the Company's planned BLA for RGX-121 could result in receipt of a Rare Pediatric Disease Priority Review Voucher in 2025, assuming the statutory criteria are met. We completed a successful pre-BLA meeting with the FDA and will initiate a rolling BLA submission using the accelerated approval pathway in the third quarter of 2024, potentially making RGX-121 the first approved gene therapy and one-time treatment for MPS II. We expect to share additional safety and efficacy data from the Phase I/II/III CAMPSIITE trial in the second half of 2024.

Overview of Our NAV Technology Platform

In addition to our internal product development efforts, we also selectively license the NAV Technology Platform to other leading biotechnology and pharmaceutical companies, which we refer to as NAV Technology Licensees. As of March 31, 2024 June 30, 2024, our NAV Technology Platform was being applied in one commercial product, Zolgensma®, and the preclinical and clinical development of a number of other licensed products. Licensing the NAV Technology Platform allows us to maintain our internal product development focus on our core disease indications and therapeutic areas while still expanding the NAV gene therapy pipeline, developing a greater breadth of treatments for patients, providing additional technological and potential clinical proof-of-concept for our NAV Technology Platform and creating potential additional revenue opportunities.

26

[Table of Contents](#)

Financial Overview

Revenues

Our revenues to date consist primarily of license and royalty revenue resulting from the licensing of our NAV Technology Platform and other intellectual property rights. We have not generated any revenues from commercial sales of our own products. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval and adequate labeling, our ability to generate future revenues will be materially compromised.

We license our NAV Technology Platform and other intellectual property rights to other biotechnology and pharmaceutical companies, including collaborators for the joint development and commercialization of our product candidates. The terms of the licenses vary, and licenses may be exclusive or non-exclusive and may be sublicensable by the licensee. Licenses may grant intellectual property rights for purposes of internal and preclinical research and development only, or may include the rights, or options to obtain future rights, to commercialize drug therapies for specific diseases using the NAV Technology Platform and other licensed rights. License agreements generally have a term at least equal to the life of the underlying patents, but are terminable at the option of the licensee. Consideration from licensees under our license agreements may include: (i) up-front and annual fees, (ii) milestone

payments based on the achievement of certain development and sales-based milestones, (iii) sublicense fees, (iv) royalties on sales of licensed products and (v) other consideration payable upon optional goods and services purchased by licensees.

[Table of Contents](#)

Future license and royalty revenues are dependent on the successful development and commercialization of licensed products, which is uncertain, and revenues may fluctuate significantly from period to period. Additionally, we may never receive consideration in our license agreements that is contemplated on option fees, development and sales-based milestone payments, royalties on sales of licensed products or sublicense fees, given the contingent nature of these payments. Our revenues are concentrated among a low number of licensees and licenses are terminable at the option of the licensee. The termination of our licenses by licensees may materially impact the amount of revenue we recognize in future periods.

Zolgensma Royalties

Royalty revenue to date consists primarily of royalties on net sales of Zolgensma, which is marketed by Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the treatment of spinal muscular atrophy (SMA). Zolgensma is a licensed product under our license agreement with Novartis Gene Therapies for the development and commercialization of treatments for SMA using the NAV Technology Platform.

Collaboration and License Agreement with AbbVie

In September 2021, we entered into a collaboration and license agreement with AbbVie Global Enterprises Ltd. (AbbVie), a subsidiary of AbbVie Inc., to jointly develop and commercialize ABBV-RGX-314 (the AbbVie Collaboration Agreement). The AbbVie Collaboration Agreement may materially impact our future revenues, research and development expenses, other operating expenses and operating cash flows associated with the development and commercialization of ABBV-RGX-314. For additional information regarding the AbbVie Collaboration Agreement, please refer to Note 9, "License and Collaboration Agreements—AbbVie Collaboration and License Agreement" to the accompanying unaudited consolidated financial statements.

Operating Expenses

Our operating expenses consist primarily of cost of revenues, research and development expenses and general and administrative expenses. Personnel costs including salaries, wages, benefits, bonuses and stock-based compensation expense, comprise a significant component of research and development and general and administrative expenses. We allocate indirect expenses associated with our facilities, information technology costs, depreciation and other overhead costs between research and development and general and administrative categories based on employee headcount and the nature of work performed by each employee or using other reasonable allocation methodologies.

[Table of Contents](#)

Cost of Revenues

Our cost of revenues consists primarily of upstream fees due to our licensors as a result of revenue generated from the licensing of our NAV Technology Platform and other intellectual property rights, including sublicense fees and royalties on net sales of licensed products. Sublicense fees are

based on a percentage of license fees received by us from licensees and are recognized in the period that the underlying license revenue is recognized. Royalties are based on a percentage of net sales of licensed products by licensees and are recognized in the period that the underlying sales occur. Future costs of revenues are uncertain due to the nature of our license agreements and significant fluctuations in cost of revenues may occur from period to period.

Research and Development Expense

Our research and development expenses consist primarily of:

- salaries, wages and personnel-related costs, including benefits, travel and stock-based compensation, for our scientific personnel and others performing research and development activities;
- costs related to executing preclinical studies and clinical trials;
- costs related to acquiring, developing and manufacturing materials for preclinical studies and clinical trials;
- fees paid to consultants and other third-parties who support our product candidate development;
- other costs in seeking regulatory approval of our product candidates; and
- direct costs and allocated costs related to laboratories and facilities, depreciation expense, information technology and other overhead.

24

Table of Contents

Up-front fees incurred in obtaining technology licenses for research and development activities, as well as associated milestone payments, are charged to research and development expense as incurred if the technology licensed has no alternative future use.

We expect to continue to incur significant research and development expenses for the foreseeable future as we continue the development of our product candidates and engage in early research and development for prospective product candidates and new technologies. The following table summarizes our research and development expenses incurred during the three and six months ended **March 31, 2024** **June 30, 2024** and 2023 (in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Direct Expenses						
ABBV-RGX-314	\$ 8,791	\$ 5,036	\$ 9,179	\$ 5,333	\$ 17,969	\$ 10,369
RGX-202	2,967	4,577	2,211	1,568	5,178	6,145
RGX-121	4,293	1,795	3,488	5,837	7,781	7,632
Other product candidates	1,021	1,670	862	2,867	1,884	4,538
Total direct expenses	17,072	13,078	15,740	15,605	32,812	28,684
Unallocated Expenses						
Platform and new technologies	7,447	11,349	4,203	11,556	11,650	22,905
Personnel-related	22,168	25,475	20,846	23,943	43,014	49,417
Facilities and depreciation expense	7,080	7,077	7,044	7,273	14,124	14,350
Other unallocated	1,077	1,537	1,036	1,509	2,113	3,046
Total unallocated expenses	37,772	45,438	33,129	44,281	70,901	89,718
Total research and development	\$ 54,844	\$ 58,516	\$ 48,869	\$ 59,886	\$ 103,713	\$ 118,402

Direct expenses related to the development of ABBV-RGX-314 include \$21.3 million and \$46.2 million for the three and six months ended March 31, 2024 June 30, 2024, respectively, and 2023 include \$25.0 million \$18.2 million and \$18.5 million \$36.7 million for the three and six months ended June 30, 2023, respectively, in net cost reimbursement from AbbVie under our eye care collaboration which were recorded as a reduction of research and development expenses. Net cost reimbursement from AbbVie includes reimbursement of personnel and overhead costs attributable to the development of ABBV-RGX-314, the underlying costs of which are reported as unallocated expenses in the table above. We typically utilize our employee and infrastructure resources across our development programs. As a result, we generally do not allocate personnel and other internal costs, such as facilities and other overhead costs, to specific product candidates or development programs.

28

[Table of Contents](#)

Platform and new technologies reported in the table above include direct costs not identifiable with a specific lead product candidate, including costs associated with our research and development platform used across programs, process development, manufacturing analytics and early research and development for prospective product candidates and new technologies.

Direct expenses related to the development of product candidates for which we have discontinued internal development are included in other product candidates in the table above. We expect to continue to incur minor development expenses associated with long-term follow up studies for certain discontinued product candidates.

General and Administrative Expense

Our general and administrative expenses consist primarily of salaries, wages and personnel-related costs, including benefits, travel and stock-based compensation, for employees performing functions other than research and development. This includes certain personnel in executive, commercial, corporate development, finance, legal, human resources, information technology, facilities and administrative support functions. Additionally, general and administrative expenses include costs associated with accounting, legal, commercial and other corporate advisory services, obtaining and maintaining patents, insurance, information systems and other general corporate activities, as well as facility-related costs and other corporate overhead costs not otherwise allocated to research and development expense, professional fees for accounting, legal, commercial and other advisory services, expenses associated with obtaining and maintaining patents, insurance costs, costs of our information systems and other general corporate activities. expense. We expect that our general and administrative expenses will increase as we continue to develop, and potentially commercialize, our product candidates.

Other Income (Expense)

Interest Income from Licensing

In accordance with our revenue recognition policy, interest income from licensing consists of imputed interest recognized from significant financing components identified in our license agreements with NAV Technology Licensees as well as interest income accrued on unpaid balances due from licensees.

25

[Table of Contents](#)

Investment Income

Investment income consists of interest income earned and gains and losses realized from our cash equivalents, marketable securities and non-marketable equity securities. Cash equivalents are comprised of money market mutual funds and highly liquid debt securities with original maturities of 90 days or less at acquisition. Marketable securities are comprised of available-for-sale debt securities.

Interest Expense

Interest expense consists primarily of interest imputed on the liability related to the sale of future Zolgensma royalties to entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Interest expense is recognized using the effective interest method, based on our estimate of total royalty payments expected to be received by HCR under the royalty purchase agreement. For further information regarding the royalty purchase agreement with HCR, please refer to Note 7, "Liability Related to Sale of Future Royalties" to the accompanying unaudited consolidated financial statements.

Critical Accounting Policies and Estimates

This Management's Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are fully described in Note 2 to the accompanying unaudited consolidated financial statements and in Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no significant changes in our critical accounting policies and estimates since December 31, 2023.

29

[Table of Contents](#)

Results of Operations

Our consolidated results of operations were as follows (in thousands):

	Three Months Ended March			Three Months Ended June 30,			Six Months Ended June 30,		
	31,								
	2024	2023	Change	2024	2023	Change	2024	2023	Change
Revenues									
License and royalty revenue	\$ 15,622	\$ 19,138	\$ (3,516)	\$ 22,295	\$ 19,977	\$ 2,318	\$ 37,917	\$ 39,115	\$ (1,198)
Total revenues	15,622	19,138	(3,516)	22,295	19,977	2,318	37,917	39,115	(1,198)
Operating Expenses									
Cost of revenues	4,283	4,112	171	10,579	9,475	1,104	14,862	13,587	1,275
Research and development			(3,672)			(11,017)	103,713	118,402	(14,689)
	54,844	58,516		48,869	59,886				

General and administrative	18,291	22,634	(4,343)	18,855	23,698	(4,843)	37,146	46,332	(9,186)
Impairment of long-lived assets	2,101	—	2,101	—	—	—	2,101	—	2,101
Other operating expenses (income)	(34)	33	(67)	29	26	3	(5)	59	(64)
Total operating expenses	79,485	85,295	(5,810)	78,332	93,085	(14,753)	157,817	178,380	(20,563)
Loss from operations	(63,863)	(66,157)	2,294	(56,037)	(73,108)	17,071	(119,900)	(139,265)	19,365
Other Income (Expense)									
Interest income from licensing	37	70	(33)	29	40	(11)	66	110	(44)
Investment income	2,469	2,166	303	3,468	2,127	1,341	5,937	4,293	1,644
Interest expense	(1,973)	(2,755)	782	(449)	(1,120)	671	(2,422)	(3,875)	1,453
Total other income (expense)	533	(519)	1,052						
Total other income	3,048	1,047	2,001	3,581	528	3,053			
Net loss	\$ (63,330)	\$ (66,676)	\$ 3,346	\$ (52,989)	\$ (72,061)	\$ 19,072	\$ (116,319)	\$ (138,737)	\$ 22,418

26

Table of Contents

Comparison of the Three Months Ended March 31, 2024 June 30, 2024 and 2023

License and Royalty Revenue. License and royalty revenue decreased increased by \$3.5 million \$2.3 million, from \$19.1 million \$20.0 million for the three months ended March 31, 2023 June 30, 2023 to \$15.6 million \$22.3 million for the three months ended March 31, 2024 June 30, 2024. The decrease increase was primarily attributable to non-recurring development milestone revenue recognized in the first quarter of 2023 and Zolgensma royalty revenues, which decreased increased by \$0.9 million \$2.8 million, from \$16.1 million \$19.0 million for the first second quarter of 2023 to \$15.2 million \$21.8 million for the first second quarter of 2024. Novartis reported Zolgensma sales of \$349 million for the second quarter of 2024, an increase of 12% from the second quarter of 2023. As reported by Novartis, Zolgensma sales of Zolgensma grew particularly in the first quarter of 2024 were \$295 million, a decrease of 5% from the first quarter of 2023, U.S. and established markets continue to treat mainly incident patients.

Research and Development Expense. Research and development expenses decreased by \$3.7 million \$11.0 million, from \$58.5 million \$59.9 million for the three months ended March 31, 2023 June 30, 2023 to \$54.8 million \$48.9 million for the three months ended March 31, 2024 June 30, 2024. The decrease was primarily attributable to the following:

- a decrease of \$7.1 million \$4.7 million in manufacturing expenses and other costs of clinical supply for our lead product candidates, largely driven by ABBV-RGX-314 and RGX-202 clinical supply costs;
- a decrease of \$3.3 million \$3.1 million in personnel-related costs for research and development personnel, including a \$1.2 million \$0.8 million decrease in stock-based compensation expense, largely driven by the reduction in workforce associated with our corporate restructuring implemented in the fourth quarter of 2023;
- a decrease of \$3.1 million in preclinical activities and other early stage research and development; and
- a decrease of \$2.0 million \$2.2 million in costs for laboratories and facilities used by research and development personnel, including a \$0.4 million decrease in depreciation expense allocated to research and development functions, primarily driven by a decrease in laboratory supplies and consumables.

The decrease in research and development expenses was partially offset by an increase of \$9.2 million \$2.6 million in costs associated with clinical trial activities, largely driven by clinical trial expenses for ABBV-RGX-314 RGX-202 and RGX-121. RGX-202.

General and Administrative Expense. General and administrative expenses decreased by \$4.3 million \$4.8 million, from \$22.6 million \$23.7 million for the three months ended March 31, 2023 June 30, 2023 to \$18.3 million \$18.9 million for the three months ended March 31, 2024 June 30, 2024. The decrease was primarily attributable to professional services and consulting fees, including legal and other corporate advisory services.

30

[Table of Contents](#)

Comparison of the Six Months Ended June 30, 2024 and 2023

License and Royalty Revenue. License and royalty revenue decreased by \$1.2 million, from \$39.1 million for the six months ended June 30, 2023 to \$37.9 million for the six months ended June 30, 2024. The decrease was primarily attributable to non-recurring development milestone revenue recognized in the first half of 2023. The decrease was partially offset by Zolgensma royalty revenues, which increased by \$1.9 million, from \$35.1 million for the first half of 2023 to \$37.0 million for the first half of 2024. As reported by Novartis, sales of Zolgensma for the first half of 2024 were \$644 million, an increase of 4% from the first half of 2023, and established markets continue to treat mainly incident patients.

Research and Development Expense. Research and development expenses decreased by \$14.7 million, from \$118.4 million for the six months ended June 30, 2023 to \$103.7 million for the six months ended June 30, 2024. The decrease was primarily attributable to the following:

- a decrease of \$2.8 million \$11.8 million in manufacturing expenses and other costs of clinical supply for our lead product candidates, largely driven by ABBV-RGX-314 and RGX-202 clinical supply costs;
- a decrease of \$6.4 million in personnel-related costs for research and development personnel, including a \$1.9 million decrease in stock-based compensation expense, largely driven by the reduction in workforce associated with our corporate restructuring implemented in the fourth quarter of 2023;
- a decrease of \$4.2 million in costs for laboratories and facilities used by research and development personnel, including a \$0.4 million decrease in depreciation expense allocated to research and development functions, primarily driven by a decrease in laboratory supplies and consumables;
- a decrease of \$3.1 million in preclinical activities and other early stage research and development.

The decrease in research and development expenses was partially offset by an increase of \$11.8 million in costs associated with clinical trial activities, largely driven by clinical trial expenses for ABBV-RGX-314 and RGX-202.

General and Administrative Expense. General and administrative expenses decreased by \$9.2 million, from \$46.3 million for the six months ended June 30, 2023 to \$37.1 million for the six months ended June 30, 2024. The decrease was primarily attributable to the following:

- a decrease of \$7.0 million in professional services and consulting fees, including legal and other corporate advisory services; and
- a decrease of \$1.3 million \$1.9 million in personnel-related costs for general and administrative personnel, including a \$0.4 million \$0.7 million decrease in stock-based compensation expense, largely driven by the reduction in workforce associated with our corporate restructuring implemented in the fourth quarter of 2023.

Liquidity and Capital Resources

Sources of Liquidity

As of March 31, 2024 June 30, 2024, we had cash, cash equivalents and marketable securities of \$380.5 million \$327.3 million, which were primarily derived from the sale of our common stock and pre-funded warrants described below and license fees received under the AbbVie Collaboration Agreement. We expect that our cash, cash equivalents and marketable securities as of March 31, 2024 June 30, 2024 will enable us to fund our operating expenses and capital expenditure requirements, and are sufficient to meet our financial commitments and obligations, for at least the next 12 months from the date of this report based on our current business plan.

In March 2024, we completed a public offering of 4,565,260 shares of our common stock at a price of \$23.00 per share and 1,521,740 pre-funded warrants to purchase shares of our common stock at a price of \$22.9999 per pre-funded warrant, which equaled the public offering price per share of the common stock less the \$0.0001 exercise price of each pre-funded warrant. The aggregate net proceeds received from the offering were \$131.1 million, net of underwriting discounts and commissions and offering expenses.

31

[Table of Contents](#)

We intend to devote the majority of our current capital to preclinical research, clinical development, seeking regulatory approval of our product candidates and, if approved, commercialization of our product candidates, as well as additional capital expenditures needed to support these activities. Because of the numerous risks and uncertainties associated with the development and commercialization of gene therapy product candidates, we are unable to estimate the total amount of operating expenditures and capital outlays necessary to complete the development of our product candidates. While we expect the pipeline prioritization and corporate restructuring implemented in November 2023 to result in cost savings, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the restructuring. In addition, we may not achieve the expected benefits of any cost reduction measures on our currently anticipated timeline, or at all. Furthermore, our estimates are based on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect which could accelerate our liquidity needs.

27

[Table of Contents](#)

At-the-Market Offering Program

In September 2023, we entered into an ATM Equity OfferingSM Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to \$150.0 million from time to time through BofA, acting as our sales agent (the ATM Program). We intend to use proceeds obtained from the sale of shares under the ATM Program, if any, for general corporate purposes. As of **March 31, 2024** **June 30, 2024**, no shares of common stock had been sold under the ATM Program.

Cash Flows

Our consolidated cash flows were as follows (in thousands):

	Three Months Ended March 31,		Six Months Ended June 30,	
	2024	2023	2024	2023
Net cash used in operating activities	\$ (55,455)	\$ (80,918)	\$ (100,952)	\$ (128,240)
Net cash provided by investing activities	13,183	63,094	12,915	118,312
Net cash provided by (used in) financing activities	120,725	(9,037)	111,280	(18,199)
Net increase (decrease) in cash and cash equivalents and restricted cash	\$ 78,453	\$ (26,861)	\$ 23,243	\$ (28,127)

Cash Flows from Operating Activities

Our net cash used in operating activities for the ~~three~~ six months ended ~~March 31, 2024~~ June 30, 2024 decreased by ~~\$25.5 million~~ \$27.3 million from the ~~three~~ six months ended ~~March 31, 2023~~ June 30, 2023, largely as a result of lower operating expenses and increased cost reimbursement received from AbbVie under our ABBV-RGX-314 collaboration in the first ~~quarter~~ half of 2024. We expect to continue to incur regular net cash outflows from operations for the foreseeable future as we continue the development and advancement of our product candidates and other research programs.

For the ~~three~~ six months ended ~~March 31, 2024~~ June 30, 2024, our net cash used in operating activities of ~~\$55.5 million~~ \$101.0 million consisted of a net loss of ~~\$63.3 million~~ \$116.3 million and unfavorable changes in operating assets and liabilities of ~~\$8.2 million~~ \$12.2 million, offset by adjustments for non-cash items of ~~\$16.0 million~~ \$27.6 million. The changes in operating assets and liabilities include a decrease in total accounts payable and accrued expenses and other current liabilities of \$14.0 million, which was driven largely by decreases in accrued sublicense fees, royalties and personnel-related expenses. Other changes in operating working capital occurred in the normal course of business. Adjustments for non-cash items primarily consisted of stock-based compensation expense of \$19.0 million and depreciation and amortization expense of \$8.2 million.

For the six months ended June 30, 2023, our net cash used in operating activities of \$128.2 million consisted of a net loss of \$138.7 million and unfavorable changes in operating assets and liabilities of \$19.5 million, offset by adjustments for non-cash items of \$30.0 million. The changes in operating assets and liabilities include a net decrease in total accounts payable and accrued expenses and other current liabilities of ~~\$8.6 million~~ \$10.6 million, which ~~were was~~ driven primarily by ~~decreases in accrued sublicense fees, royalties~~ the timing of invoices from suppliers and ~~personnel-related expenses~~, associated payments made by the Company as of the end of the period, and an increase in ~~total prepaid expenses and~~ other current assets of ~~\$6.8 million~~ \$14.1 million, which was driven primarily by an increase in net cost reimbursement due from AbbVie under our ABBV-RGX-314 collaboration. The unfavorable changes in operating assets and liabilities were partially offset by a decrease in accounts receivable of \$7.1 million, which was driven primarily by a reduction in Zolgensma royalties receivable. Other changes in operating working capital occurred in the normal course of business. Adjustments for non-cash items primarily consisted of stock-based compensation expense of ~~\$9.6 million~~ \$21.7 million and depreciation and amortization expense of ~~\$4.2 million~~ \$8.6 million.

For the three months ended March 31, 2023, our net cash used in operating activities of \$80.9 million consisted of a net loss of \$66.7 million and unfavorable changes in operating assets and liabilities of \$29.6 million, offset by adjustments for non-cash items of \$15.4 million. The changes in operating assets and liabilities include a decrease in total accounts payable and accrued expenses and other current liabilities of \$18.5 million, which were driven primarily by decreases in accrued sublicense fees, royalties and personnel-related expenses, and an increase in total prepaid expenses and other current assets of \$15.3 million, which was driven primarily by an increase in net cost reimbursement due from AbbVie under our ABBV-RGX-314 collaboration. Other changes in operating working capital occurred in the normal course of business. Adjustments for non-cash items primarily consisted of stock-based compensation expense of \$11.2 million and depreciation and amortization expense of \$4.2 million.

Cash Flows from Investing Activities

For the three months ended March 31, 2024, our net cash provided by investing activities consisted of \$68.9 million in maturities of marketable debt securities, offset by \$55.2 million to purchase marketable debt securities and \$0.6 million to purchase property and equipment.

For the three months ended March 31, 2023, our net cash provided by investing activities consisted of \$67.9 million in maturities of marketable debt securities, offset by \$4.8 million to purchase property and equipment.

For the six months ended June 30, 2024, our net cash provided by investing activities consisted of \$151.7 million in maturities of marketable debt securities, offset by \$137.7 million used to purchase marketable debt securities and \$1.0 million used to purchase property and equipment.

For the six months ended June 30, 2023, our net cash provided by investing activities consisted of \$175.5 million in maturities of marketable debt securities, offset by \$49.8 million used to purchase marketable debt securities and \$7.4 million used to purchase property and equipment.

Cash Flows from Financing Activities

For the ~~three~~ **six** months ended ~~March 31, 2024~~ **June 30, 2024**, our net cash provided by financing activities primarily consisted of ~~\$131.6 million~~ **\$131.4 million** in net proceeds received from the public offering of common stock and pre-funded warrants completed in March 2024, net of underwriting discounts and commissions and other offering expenses paid during the period, and ~~\$1.3 million~~ **\$1.5 million** in proceeds received from the exercise of stock options and issuance of common stock under our employee stock purchase plan. Our net cash provided by financing activities was partially offset by ~~\$11.2 million~~ **\$20.5 million** of Zolgensma royalties paid to HCR, net of imputed interest, under our royalty purchase agreement.

For the ~~three~~ **six** months ended ~~March 31, 2023~~ **June 30, 2023**, our net cash used in financing activities primarily consisted of ~~\$9.7 million~~ **\$19.6 million** of Zolgensma royalties paid to HCR, net of imputed interest, under our royalty purchase agreement, and was partially offset by ~~\$1.1 million~~ **\$1.8 million** in proceeds received from the exercise of stock options and issuance of common stock under our employee stock purchase plan.

Additional Capital Requirements

Our material capital requirements from known contractual and other obligations primarily relate to vendor service contracts and purchase commitments, in-license agreements, operating lease agreements and our Zolgensma royalty purchase agreement with HCR. Our material commitments and obligations are further described in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended December 31, 2023, and in the notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. Other than the changes described in the notes to the unaudited consolidated financial statements accompanying this Quarterly Report on Form 10-Q, including Note 6, "Leases," there have been no material changes to our commitments and obligations since December 31, 2023.

Future Funding Requirements

We have incurred cumulative losses since our inception and had an accumulated deficit of ~~\$768.4 million~~ **\$821.4 million** as of ~~March 31, 2024~~ **June 30, 2024**. Our transition to recurring profitability is dependent upon achieving a level of revenues adequate to support our cost structure, which depends heavily on the successful development, approval and commercialization of our product candidates. We do not expect to achieve such revenues, and expect to continue to incur losses, for at least the next several years. We expect to continue to incur significant research and development and general and administrative expenses for the foreseeable future as we continue the development of, and seek regulatory approval for, our product candidates. Subject to obtaining regulatory approval for our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. Additionally, we expect to continue to incur capital expenditures associated with building out additional laboratory and manufacturing capacity to further support the development of our product candidates and potential commercialization efforts. As a result, we will need significant additional capital to fund our operations, which we may obtain through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements.

Our future capital requirements will depend on many factors, including:

- the timing of enrollment, commencement and completion of our clinical trials;
- the results of our clinical trials;
- the results of our preclinical studies for our product candidates and any subsequent clinical trials;
- the scope, progress, results and costs of drug discovery, laboratory testing, preclinical development and clinical trials for our product candidate;
- the costs associated with building out additional laboratory and manufacturing capacity;

Table of Contents

- the costs, timing and outcome of regulatory review of our product candidates;
- the costs of future product sales, medical affairs, marketing, manufacturing and distribution activities for any of our product candidates for which receive marketing approval;
- revenue, if any, received from commercial sales of our products, should any of our product candidates receive marketing approval;
- revenue received from commercial sales of Zolgensma and the timing and amount of Zolgensma royalties paid to HCR under our royalty purchase agreement;

Table of Contents

- revenue received from other commercial sales of our licensees' and collaborators' products, should any of their product candidates receive marketing approval, and other revenue received under our licensing agreements and collaborations;
- the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
- our current licensing agreements or collaborations remaining in effect, including the AbbVie Collaboration Agreement, and our ability to timely achieve any milestones set forth in such agreements or collaborations;
- our ability to establish and maintain additional licensing agreements or collaborations on favorable terms, if at all; and
- the extent to which we acquire or in-license other product candidates and technologies.

Many of these factors are outside of our control. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory and marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, and any commercial milestones or royalty payments under our licensing agreements, will be derived from or based on sales of products that may not be commercially available for many years, if at all. In addition, revenue from our NAV Technology Platform licensing is dependent in part on the clinical and commercial success of our licensing partners, including the commercialization of Zolgensma, and on maintaining our license agreements with our licensor partners, including GlaxoSmithKline LLC and The Trustees of the University of Pennsylvania. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.

The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. Adequate additional financing may not be available to us on acceptable terms, or at all. We also could be required to seek funds through arrangements with partners or otherwise others that may require us to relinquish rights to our intellectual property, our product candidates or otherwise agree to terms unfavorable to us.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

[Table of Contents](#)

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

For information regarding market risk, refer to Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our exposure to market risk during the **three** **six** months ended **March 31, 2024** **June 30, 2024**.

Item 4. Controls and Procedures.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of **March 31, 2024** **June 30, 2024**. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of **March 31, 2024** **June 30, 2024**, our disclosure controls and procedures were effective at a reasonable assurance level.

30

[Table of Contents](#)

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended **March 31, 2024** **June 30, 2024** that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

31 35

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we are party to various lawsuits, claims or other legal proceedings that arise in the normal course of our business. We do not believe that we are currently party to any pending legal actions that could reasonably be expected to have a material adverse effect on our business, financial condition, results of operations or cash flows.

Item 1A. Risk Factors.

Our material risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes from the risk factors previously disclosed in such filing.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

Rule 10b5-1 Trading Plans

The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for **During** the three months ended **March 31, 2024**, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) ("Rule 10b5-1 Plan"), were as follows:

Name	Title	Action	Date Adopted	Expiration Date	Rule 10b5-1 Trading	Aggregate # of Securities to be Purchased/Sold (a)
					Plan Provides for Purchase/Sale	
Olivier Danos	Executive Vice President, Chief Scientific Officer	Adoption	3/15/2024	3/1/2025	Sale	138,094
Curran Simpson	Executive Vice President, Chief Operating Officer	Adoption	3/15/2024	2/28/2025	Sale	67,834
A.N. "Jerry" Karabelas	Director	Adoption	3/25/2024	3/1/2025	Sale	74,375
Vittal Vasista	Executive Vice President, Chief Financial Officer	Adoption	3/27/2024	3/26/2026	Sale	228,610

(a) The aggregate number of shares in this column includes shares that may be forfeited or withheld to satisfy exercise price and tax withholding obligations at the time of vesting.

Other than as described above, during the three months ended March 31, 2024 June 30, 2024, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).

32 36

[Table of Contents](#)

Item 6. Exhibits.

Exhibit Number	Description	Incorporated by Reference			Filed or Furnished Herewith	Description	Incorporated by Reference			Filed or Furnished Herewith
		Form	Exhibit Number	Filing Date			Form	Exhibit Number	Filing Date	
3.1	Restated Certificate of Incorporation	8-K	3.1	6/7/21		Restated Certificate of Incorporation	8-K	3.1	6/7/21	
3.2	Amended and Restated Bylaws	8-K	3.2	9/22/15		Amended and Restated Bylaws	8-K	3.2	9/22/15	
4.1	Form of Pre-funded Warrant	8-K	4.1	3/11/24						
10.1*	Employment Agreement effective as of July 1, 2024 between the Registrant and Curran Simpson				X					
10.2*	Consulting and Employment Separation Agreement effective as of July 1, 2024 between the Registrant and Kenneth T. Mills				X					
31.1	Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002				X	Certification of the Chief Executive Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002				X
31.2	Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002				X	Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002				X

32.1	Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350	X	Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350	X
101	The following materials from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets (ii) Consolidated Statements of Operations and Comprehensive Loss (iii) Consolidated Statements of Stockholders' Equity (iv) Consolidated Statements of Cash Flows (v) Notes to Consolidated Financial Statements	X	The following materials from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets (ii) Consolidated Statements of Operations and Comprehensive Loss (iii) Consolidated Statements of Stockholders' Equity (iv) Consolidated Statements of Cash Flows (v) Notes to Consolidated Financial Statements	X
104	The cover page from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 formatted in Inline XBRL (included in Exhibit 101)		The cover page from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 formatted in Inline XBRL (included in Exhibit 101)	

* Management contract or compensatory plan or arrangement.

The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

33 37

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REGENXBIO Inc.

Dated: May 8, 2024 August 1, 2024

/s/ Kenneth T. Mills Curran Simpson

Kenneth T. Mills Curran Simpson

President and Chief Executive Officer
(Principal Executive Officer)

Dated: May 8, 2024 August 1, 2024


/s/ Vittal Vasista

Vittal Vasista

Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

34 38

EXHIBIT 10.1



This Employment Agreement (this "Agreement") is entered into and made effective as of July 1, 2024, by and between Curran Simpson (the "Employee") and REGENXBIO Inc., a Delaware corporation (the "Company").

1. Position.

- (a) During your employment with the Company pursuant to this Agreement, you will hold the title of President & Chief Executive Officer (CEO). As CEO you shall report directly to the Chairman of the Board. By signing this Agreement, you agree to perform the duties and fulfill the responsibilities normally inherent in the position of CEO and such other duties and responsibilities as may from time to time reasonably be assigned to you. You will be primarily located and working from our headquarters office, located at Rockville, Maryland.
- (b) You agree that, to the best of your ability and experience, you will at all times loyally and conscientiously perform all of the duties and obligations required of and from you pursuant to the express and implicit terms hereof, and to the reasonable satisfaction of the Company. During the term of your employment with the Company, you further agree that (i) you will devote substantially all of your business time and attention to the business of the Company, (ii) the Company will be entitled to all of the benefits and profits arising from or incident to all such business services, (iii) you will not render commercial or professional services of any nature to any person or organization outside of the Company without the prior written approval of the Company's Board of Directors (the "Board"), and (iv) you will not directly or indirectly engage or participate in any business that is competitive in any manner with the business of the Company. Notwithstanding the above, you may continue, on your own time, at your own expense and so as to not interfere with your duties and responsibilities at the Company to (i) subject to the prior approval of the Company's Chief Executive Officer, serve as a member of an advisory board or board of directors of other companies that are not competitive in any manner with the Company, (ii) accept speaking or presentation engagements in exchange for honoraria, and (iii) participate in civic, educational, charitable or fraternal organizations. This Agreement does not prevent you from owning no more than one percent (1%) of the outstanding equity securities of a corporation whose stock is listed on a national stock exchange and is a competitor or potential competitor of the Company.

2. Compensation.

- (a) **Base Salary.** Your starting base salary will be \$610,000.00 per year, less applicable taxes, deductions, and withholdings, and payable in accordance with the Company's standard pay practices and schedule, which is currently bi-weekly. **Incentive Bonus.** You shall be eligible for an annual incentive bonus with a target amount equal to 60% of your Base Salary (the "Annual Target Bonus").

1

Such bonus (if any) shall be awarded based on criteria established in advance by the Board or the Compensation Committee of the Board (the "Compensation Committee"). Any incentive bonus earned by you for any fiscal year shall only be paid to you if you remain employed by the Company through the payment date for the bonus. The Company shall determine when to pay to you any earned incentive bonus, but shall in no event pay such bonus more than 2½ months following the close of the fiscal year for which it is earned. Any bonus for the fiscal year in which your employment begins will be prorated, based on the number of days you are employed by the Company during that fiscal year. Employees starting employment on or after October 1 are not eligible for a bonus for that fiscal year. The determinations of the Board or the Compensation Committee with respect to such bonus shall be final and binding.

- (b) **Stock Options and Restricted Stock Units ("RSUs").** Subject to the approval of the Company's Board of Directors, Compensation Committee, you will be granted an equity package that has a targeted equity value of \$2.5 million based on the July 1, 2024, share price. The awards shall be delivered in equity (RSUs, stock options ("Options")) and have terms and conditions consistent with awards made to other similarly situated officers of the Company pursuant to the terms of the applicable 2015 Equity Incentive Plan and will be subject to the vesting schedule contained herein.
- (i) The Options shall vest as follows: Twenty-Five percent (25%) of the shares subject to the Option will vest at 12 months of continuous service, and the balance will vest in equal monthly installments over the next 36 months of continuous service, as described in the applicable agreement governing the Option; and
- (ii) The RSUs will vest as follows: Twenty-Five (25%) of the RSUs will vest on each of the first, second, third fourth anniversaries of the first day of the month in which the RSUs are granted, as described in the applicable agreement governing the RSUs.
- (c) **Application of Clawback Policy.** Any compensation that is granted, earned or vested wholly or in part based on stock price, total shareholder return and/or the attainment of any financial reporting measure (or measure derived from such financial reporting measure) shall be subject to recoupment by the Company in accordance with any Company clawback policy that is from time to time in effect, including, for the avoidance of doubt, any clawback policy adopted to comply with applicable law or stock exchange listing standard.
- (d) **Annual Review.** Your compensation will be reviewed by the Board or Compensation Committee annually.
3. **Benefits.** As an employee of the Company, you will also be eligible to receive certain employee benefits including paid time off and medical, dental, life, and long-term disability insurance. You will also be eligible to participate in our 401(k) savings plan.
4. **At-Will Employment; Proprietary Information and Inventions Agreement.** Employment with the Company is for no specific period of time. Your employment with the Company is "at will," meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. In addition, you should note that the Company may modify your job title, salary or benefits at its discretion.

You agree and affirm that your continued employment with the Company is contingent upon your agreement to comply with the Proprietary Information and Inventions Agreement signed by you.

5. **Indemnification.** The Company shall indemnify you to the fullest extent allowed by law, in accordance with the terms of the Company's Certificate of Incorporation and Bylaws. You shall continue to be a party to the Company's standard Indemnification Agreement.
6. **Company Handbook.** As a Company employee, you will be expected to abide by the Company's rules of operation and standards of conduct, as amended from time to time in the Company's discretion. Specifically, you will be required to sign acknowledgments that you have read and that you understand such rules and standards, which are set forth in the Company Handbook and other written policies.
7. **Termination of Employment and Severance Benefits.**

(a) **Preconditions.** Any other provision of this Agreement notwithstanding, Subsections of this Section 7 providing for the payment of severance benefits shall not apply unless each of the following requirements is satisfied:

- (i) You have executed a general release of all known and unknown claims that you may then have against the Company or persons affiliated with the Company in a form prescribed by the Company, without alterations. You shall execute and return the release on or before the date specified by the Company in the prescribed form. The release deadline shall in no event be later than sixty (60) days after your termination of employment (the "Release Deadline"). If the 60-day period described in the prior sentence spans two calendar years, then the payments will begin on the first payroll period, following expiration of the revocation period, in the second calendar year. If you fail to return the release on or before the Release Deadline, or if you revoke the release, then you shall not be entitled to the benefits described in this Section 7; and
- (ii) You have returned all property of the Company in your possession.

(b) **Termination of Employment.** Except for the severance benefits provided below, the Company's obligations under this Agreement may be terminated upon the occurrence of any of the following events:

- (i) The Company's determination in good faith that it is terminating you for Cause ("Termination for Cause");
- (ii) The Company's determination that it is terminating you without Cause, which determination may be made by the Company at any time at the Company's sole discretion, for any or no reason ("Termination Without Cause");
- (iii) Thirty (30) days following delivery by you of a written notice to the Company stating that you are electing to terminate your employment with the Company ("Voluntary Termination");
- (iv) Following your death or Disability (as defined below); or
- (v) Your determination in good faith that you are electing to terminate

your employment with the Company for Good Reason.

- (c) **Severance Benefits.** You shall be entitled to receive severance benefits upon termination of employment only as set forth in this Section 7(c):
- (i). **Voluntary Termination.** In the event of a Voluntary Termination you shall not be entitled to receive payment of any severance benefits. You will receive payment(s) for all salary and unpaid vacation accrued as of the date of your Voluntary Termination and your benefits will be continued under the Company's then existing benefit plans and policies to the extent permitted under such plans and policies and in accordance with such plans and policies in effect on the date of your Voluntary Termination and in accordance with applicable law.
- (ii). **Involuntary Termination/No Change in Control.** If your employment is terminated under Section 7(b)(ii) or (v) above (such termination, an "Involuntary Termination"), you, or your estate or representative, if applicable, will be entitled to receive payment of severance benefits on the date of your Involuntary Termination (the "Severance Benefits"). The Severance Benefits shall consist of salary continuation for twelve (12) months of monthly Base Salary amounts; provided that if you become employed during this period, then the Company's obligation to pay Severance Benefits shall cease upon commencement of your new employment. If you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act ("COBRA") following the Separation, then the Company shall pay your monthly premium under COBRA until the earliest of (A) the date that is nine (9) months following your Involuntary Termination (the "Continuation Period"), (B) the expiration of your continuation coverage under COBRA and (C) the date when you are offered substantially equivalent health insurance coverage in connection with new employment or self-employment. Notwithstanding anything to the contrary above, if deemed necessary or advisable by the Company in its sole discretion to avoid adverse tax consequences to the Company or any employee thereof, such COBRA premium payments will be treated as taxable compensation income to you, subject to all applicable withholdings.
- (iii). **Involuntary Termination/ Change in Control.** If your employment is terminated in an Involuntary Termination immediately prior to or in the eighteen months following a Change in Control, you, or your estate or representative, if applicable, will be entitled to receive payment of severance benefits on the date of your Involuntary Termination (the "Change in Control Severance Benefits"). The Change in Control Severance Benefits shall consist of salary continuation for twelve (12) months of monthly Base Salary plus a monthly amount equal to your Annual Target Bonus divided by twelve (12). If you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act ("COBRA") following the Separation, then the Company shall pay your monthly premium under COBRA until the earliest of (A) the date that is twelve (12) months following your Involuntary Termination (the "Continuation Period"), (B) the expiration of your continuation coverage

under COBRA and (C) the date when you are offered substantially equivalent health insurance coverage in connection with new employment or self-employment. Notwithstanding anything to the contrary above, if

deemed necessary or advisable by the Company in its sole discretion to avoid adverse tax consequences to the Company or any employee thereof, such COBRA premium payments will be treated as taxable compensation income to you, subject to all applicable withholdings. If immediately prior to or following a Change in Control (as defined in the Company's 2015 Equity Incentive Plan), your employment with the Company (or the Company's successor) is terminated in an Involuntary Termination during the remaining vesting period of the options and restricted stock units then outstanding as of the date of closing of the Change in Control (the "Shares"), then one hundred percent (100%) of the unvested Shares subject to shall automatically vest.

(iv) **Termination for Cause.** In the event of your Termination for Cause, you will not be entitled to receive any severance payments. You will receive payment(s) for all salary and unpaid vacation accrued as of the date of your Termination for Cause.

(v) **Termination by Reason of Death or Disability.** In the event that your employment with the Company terminates as a result of your death or Disability (as defined below), you or your estate or representative will receive all salary and unpaid vacation accrued as of the date of your death or Disability, all severance benefits payable under Section 7(b)(ii) above (only to the extent that you were entitled to such benefits before your death) and any other benefits payable under the Company's then existing benefit plans and policies, to the extent permitted under such plans and policies and in accordance with such plans and policies in effect on the date of death or Disability and in accordance with applicable law. For purposes of this Agreement, "Disability" shall mean that you have been unable to perform your duties hereunder as the result of physical or mental incapacity lasting at least forty-five (45) consecutive calendar days or ninety (90) calendar days during any consecutive twelve-month period, after which time such incapacity is determined to be permanent by a physician chosen by the Company and its insurers and acceptable to you or to your legal representative (with such agreement on acceptability not to be unreasonably withheld).

(d) **Cause.** For purposes of this Agreement, "Cause" shall mean:

- (i) the conviction of, or the entering a plea of guilty or no contest (or pleading or accepting deferred adjudication or receiving unadjudicated probation) to or for, any felony or any crime involving moral turpitude;
- (ii) the commission of a material breach of any of the covenants, terms and provisions of this Agreement, the Proprietary Information and Inventions Agreement you have entered into as a condition of your employment, or any other agreement you enter into with the Company;
- (iii) the commission of an act of fraud, embezzlement, misappropriation, willful misconduct or breach of fiduciary duty against the Company or other similar

5

conduct materially harmful or potentially materially harmful to the Company's best interest, as determined by the Board, in its reasonable sole discretion;

- (iv) the failure to perform assigned duties or responsibilities as the CEO (other than a failure resulting from Disability (as defined below)); provided, however, that you shall be given written notice of, and shall have a ten (10) day period following such notice to cure a failure or refusal under this subclause (iv); or

- (v) the violation of any federal or state law or regulation applicable to the Company's business.
- (e) **Good Reason.** For purposes of this Agreement, "Good Reason" shall mean the occurrence of any of the following, without your written consent:
 - (i) a significant reduction in your duties or responsibilities or your removal from the position contemplated by this Agreement;
 - (ii) a significant reduction (thirty percent (30%) or more) in your base salary as in effect immediately prior to such reduction;
 - (iii) a significant reduction in the type or level of employee benefits to which you are entitled that results in a significant reduction to your overall benefits package, as determined by the Board in its sole discretion; or
 - (iv) relocation of your principal workplace by more than 35 miles from the primary office where you performed services prior to the relocation.

Good Reason will not be deemed to occur unless you give the Company written notice of the condition within 90 days after the condition comes into existence and the Company fails to remedy the condition within 30 days after receiving said notice.

8. Tax Matters.

- (a) **Withholding.** All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.
- (b) **Tax Advice.** You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.
- (c) **280G.** Notwithstanding anything contained in this Agreement to the contrary, if any of the payments or benefits received or to be received by you pursuant to this Agreement when taken together with payments and benefits provided to you under any other plans, contracts, or arrangements with the Company (all such payments and benefits, the "Total Payments"), would be subject to any excise tax (together with any interest or penalties, the "Excise Tax") imposed under Section 4999 of the Internal Revenue Code (the "Code"), then such Total Payments will be reduced to the extent necessary so that no portion thereof will be subject to the Excise Tax; provided, however, that if you would receive in the aggregate greater value (as determined under Section 280G of the Code and the regulations thereunder) on an after tax basis if the Total Payments were not subject to such reduction, then no

6

such reduction will be made. To effect the reduction described herein, if applicable, the Company will first reduce or eliminate the payments and benefits provided under this Agreement. All calculations required to be made under this Section will be made by the Company's independent public accountants, subject to the right of your representative to review the same.

- (d) **409A.** The intent of the parties is that payments and benefits under this Agreement comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder (collectively, "Code Section 409A"), and this Agreement shall be interpreted and construed in a manner that establishes an

exemption from (or compliance with) the requirements of Code Section 409A. Any terms of this Agreement that are undefined or ambiguous shall be interpreted in a manner that complies with Code Section 409A to the extent necessary to comply with Code Section 409A. For purposes of Code Section 409A, your right to receive any installment payments shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company. In no event may you, directly or indirectly, designate the calendar year of any payment to be made under this Agreement, to the extent such payment is subject to Code Section 409A. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Code Section 409A but do not satisfy an exemption from, or the conditions of, Code Section 409A.

9. Miscellaneous Provisions.

- (a) **Choice of Law.** The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Maryland, without giving effect to the principles of conflicts of law.
- (b) **Counterparts.** This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.
- (c) **Severability.** In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without such provision.
- (d) **Acknowledgment.** You acknowledge that you have had the opportunity to discuss this matter with and obtain advice from your private attorney, have had sufficient time to read, and have carefully read and fully understand, all the provisions of this Agreement, and are knowingly and voluntarily entering into this Agreement.
- (e) **Arbitration.** Any controversy or claim arising out of this Agreement and any and all claims relating to the Employee's employment with the Company shall be settled by final and binding arbitration. The arbitration shall take place in Montgomery County, Maryland, or, at the Employee's option, the County in which the Employee primarily worked when the arbitrable dispute or claim first arose. The arbitration shall be administered by the American Arbitration Association under its National Rules for the Resolution of Employment

7

Disputes. Any award or finding shall be confidential. The Employee and the Company agree to provide one another with reasonable access to documents and witnesses in connection with the resolution of the dispute. The Company shall pay the costs of arbitration. However, each party shall be responsible for its own attorneys' fees, and the arbitrator may not award attorneys' fees unless a statute or contract at issue specifically authorizes such an award. This Section 9(e) shall not apply to claims for workers' compensation benefits or unemployment insurance benefits. This Section 9(e) also shall not apply to claims concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held or sought by either the Employee or the Company (whether or not arising under the Proprietary Information and Inventions Agreement between the Employee and the Company) or with respect to any action the Company wishes to bring for injunctive relief.

- (f) **Entire Agreement.** This Agreement, together with the exhibits hereto, sets forth the terms and conditions of

employment between the parties and fully supersedes and replaces any other agreement with respect to the terms and conditions of employment.

[The remainder of this page intentionally left blank]

8

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.

REGENXBIO INC. EMPLOYEE

By: /s/ Shiva Fritsch By: /s/ Curran Simpson

Name: Shiva Fritsch Name: Curran Simpson

Title: Chief People & Communications Officer Date: June 11, 2024

9

EXHIBIT 10.2

AGREEMENT

This Consulting and Employment Separation Agreement (the “Agreement”) is entered into as of June 12, 2024, by and between REGENXBIO Inc. (“REGENXBIO”), a Delaware corporation with offices at 9804 Medical Center Drive, Rockville, Maryland 20850, and Ken Mills (“Mr. Mills”), (each a “Party” and collectively the “Parties”).

WHEREAS, Mr. Mills will voluntarily resign from his role of President and Chief Executive Officer of REGENXBIO effective July 1, 2024, but has recently been named Chairman of the Board of Directors of REGENXBIO.

WHEREAS, in addition to his roles as a member and Chairman of the board of directors of REGENXBIO (the “Board”), REGENXBIO desires to retain Mr. Mills as an independent contractor to perform consulting services for REGENXBIO, and Mr. Mills is willing to perform such services, on the terms described herein.

NOW, THEREFORE, in consideration of the mutual promises contained herein, the Parties agree as follows:

1. Description and Performance of Services

During the Term of this Agreement, Mr. Mills shall perform the services set forth in the Scope of Work attached hereto as Exhibit A as a consultant, which is incorporated by reference herein, as reasonably requested by REGENXBIO (the “Services”). Nothing in this Agreement or PIIA (as defined below) shall require Mr. Mills to disclose any information that is otherwise subject to a non-disclosure agreement, confidentiality agreement, or similar agreement, or to violate Mr. Mills’ fiduciary obligations to another company/organization. Further, to the extent permitted by Section 122(17) of the Delaware General Corporation Law or

any other applicable law in the event that the applicable entity is not incorporated, formed or organized as a corporation in the State of Delaware, REGENXBIO (for itself and on behalf of each of its wholly-owned subsidiaries) hereby renounces any interest or expectancy to participate in any corporate opportunities that are presented to Mr. Mills in connection with Mr. Mills' role as Chief Executive Officer and a member of the board of directors of other companies that are not directly competitive with REGENXBIO (collectively, the "Permitted Activities"), and waives any claim against Mr. Mills and shall indemnify Mr. Mills against any claim that Mr. Mills is liable to REGENXBIO for breach of any fiduciary duty solely by reason of Mr. Mills' participation in any such corporate opportunity arising out of any such Permitted Activity and to the extent otherwise in compliance with the terms of this Agreement and the PIIA.

2. Compensation

a. **Equity.** As consideration for Mr. Mills' performance under this Agreement, notwithstanding any contrary terms or conditions in the applicable stock option and restricted stock unit agreements, Mills' service to REGENXBIO will be deemed to be continuous between Mr. Mills' employment with REGENXBIO and performance of Mr. Mills under this Agreement for the purposes of allowing any stock options or restricted stock units on Schedule 1 to continue vesting for the Term of this Agreement, and for purposes of determining the commencement of the post-termination exercise period of any stock options. Any incentive stock options that are not

{1673505.2}

vested and exercised by the date that is three months from the Effective Date (as defined in Section 3(a) below) shall be deemed non-qualified stock options, pursuant to applicable law. The Parties agree that Schedule 1 attached to and made a part of this Agreement accurately reflects the stock options and restricted stock units held by Consultant and the vesting information related to each such grant. Mr. Mills shall not be eligible for an initial equity award grant under REGENXBIO's Compensation Program for Non-Employee Directors, but will be entitled to any future annual equity award grants on the same terms and in at least the same amount as awarded to other non-employee members of the Board.

b. **Cash.** Mr. Mills will not be paid a separate cash fee for his role as a consultant. However, beginning on July 1, 2024, Mr. Mills shall be entitled to any retainer due to a member of the Board pursuant to the REGENXBIO Compensation Program for Non-Employee Directors

c. **Bonus.** As additional consideration, Mr. Mills shall be entitled to an annual incentive bonus as defined in his Employment Agreement dated June 30, 2015, as amended (the "Employment Agreement"), for his service as President and Chief Executive Officer of REGENXBIO for the full year of 2024, as reasonably determined by the Compensation Committee of the Board of Directors of REGENXBIO, and payable in accordance with the terms set forth in the Employment Agreement.

d. **Expenses.** REGENXBIO will reimburse Mr. Mills for all reasonable, necessary and documented out-of-pocket expenses directly incurred by Mr. Mills in the performance of Services hereunder, provided that any travel be approved in advance. This shall include legal fees for the review of this Agreement not to exceed \$25,000. REGENXBIO shall reimburse Mr. Mills for such expenses upon delivery of receipts evidencing such expenses.

e. **Performance of Services.** Mr. Mills shall devote such time as reasonably necessary to carry out the Services hereunder.

f. **Benefits.** Health insurance coverage will end on July 31, 2024. Mr. Mills will be eligible to continue participating in REGENXBIO's healthcare plan in accordance with COBRA effective on August 1, 2024. Provided that Mr. Mills remains eligible for COBRA, REGENXBIO will pay Mr. Mills the cost of COBRA benefits continuation until January 31, 2025. Mr. Mills' eligibility to participate in all other REGENXBIO benefit plans will end effective on July 1, 2024.

3. Term and Termination

g. **Term.** Subject to earlier termination or extension as hereinafter provided, Mr. Mills' engagement hereunder shall be for a term of one (1) year, commencing on July 1, 2024 (the "Effective Date"), and shall only be extended thereafter upon the mutual written agreement of the Parties. The term of this Agreement, as from time to time extended or renewed, is hereafter referred to as the "Term").

h. **Termination for Breach.** If either Party breaches in any material respect any of its material obligations under this Agreement, in addition to any other right or remedy, the

{1673505.2 }

2

non-breaching Party may terminate this Agreement in the event that the breach is not cured within 30 days after receipt by the other Party of written notice of breach.

i. **Termination Other than for Breach.** Notwithstanding any other provision hereof, this Agreement may be terminated by either Party for any reason upon 30 days' prior written notice to the other Party.

j. **Effect of Termination; Survival.** Upon the expiration or other termination of this Agreement, Mr. Mills shall cease performing Services hereunder and Mr. Mills' service to REGENXBIO will be deemed to be terminated under the award agreements between REGENXBIO and Mr. Mills as of the termination date for the stock options and restricted stock units on Schedule 1. For clarity, the effects of such termination of service include, but are not limited to, the ceasing of vesting of all stock options and restricted stock units on Schedule 1 as of such termination date and the expiration of any unexpired stock options three months after such termination date, pursuant to the applicable stock option agreement between REGENXBIO and Mr. Mills (except when such termination is due to death or disability). Provided, however, expiration or termination of this Agreement will not impact any stock options, restricted stock units, or other equity or equity-based awards granted as part of Mr. Mills' service as a member of the Board of Directors. The rights and obligations set forth in Sections 3-5 and 7-12 shall survive any expiration or termination of the Agreement.

4. Proprietary Rights

REGENXBIO and Mr. Mills entered into a Proprietary Information and Inventions Agreement effective as of May 18, 2015 (the "PIIA"), which shall be incorporated into and made part of this Agreement. Notwithstanding any terms or conditions to the contrary in the PIIA, all rights, obligations and restrictions pursuant to the PIIA shall be interpreted to continue in full force and effect during the term of this Agreement as if Mr. Mills were an employee of the Company during such term; provided, however, nothing created or learned by Mr. Mills in connection with the Permitted Activities, shall be subject to or covered by the PIIA.

5. Independent Contractor Status

It is understood and agreed that effective July 1, 2024, Mr. Mills is an independent contractor and is not an employee of REGENXBIO or any of REGENXBIO's affiliates and that REGENXBIO will not make any deductions for any statutory withholdings, such as income tax, pension plans, unemployment insurance or worker's compensation. Other than as specified herein, Mr. Mills will not be entitled to participate in any medical, dental, extended health or group life insurance plans of REGENXBIO. Mr. Mills is not and shall not hold himself out to be an agent, legal representative, partner, subsidiary, joint venturer or employee of REGENXBIO, and Mr. Mills shall have no right or power to, and shall not bind or obligate REGENXBIO in any manner whatsoever or represent that Mr. Mills has any right to do so.

{1673505.2}

6. Non-Exclusive Service

Mr. Mills shall retain the right to perform work for others during the term of this Agreement, provided, however, that, Mr. Mills will not provide consulting services or other services to another company engaged in developing competitive gene therapy related products.

7. Use of Name

Neither Party may use the name of the other Party, or any variation thereon or adaptation thereof, in any endorsement, advertising, promotional sales literature or other publicity without the prior written approval of such other Party, such approval not to be unreasonably withheld, conditioned or delayed.

8. Representations, Warranties and Covenants

Mr. Mills represents, warrants and covenants to the best of his knowledge that the performance of the Services contemplated by this Agreement (a) does not and will not violate any agreements or undertakings of Mr. Mills with any other third party; (b) Mr. Mills has full authority to grant to REGENXBIO all rights granted hereunder; (c) Mr. Mills shall perform all Services in accordance with all applicable laws, rules, regulations and guidelines, including without limitation and to the extent applicable those relating to privacy and data protection; and (d) Mr. Mills is not debarred under Section 306 of the Federal Food, Drug & Cosmetic Act, or otherwise debarred, suspended, excluded, disqualified, or otherwise restricted from working on, providing services for, or participating in any U.S. Food and Drug Administration-regulated activity or federally-funded contract, grant, cooperative agreement, health care program, or research activity, or from practicing before any government agency as a consequence of misconduct of any kind, and that Mr. Mills is not, to his knowledge, presently the subject of any ongoing debarment, suspension, exclusion, disqualification, or restriction proceeding before any government agency.

9. Indemnification and D&O

a. REGENXBIO agrees to indemnify, defend and hold harmless Mr. Mills and his heirs, successors, assigns, subcontractors, employees, agents and representatives (collectively, the "Indemnified Parties"), from and against any and all loss, demands, claims, actions, damages, liability, judgments, cost and expenses, (including, but not limited to, reasonable attorneys' fees and disbursements attendant thereto), arising out of, resulting from, or in connection with REGENXBIO's breach of any duty, obligation, representation, warranty, and/or covenant in this Agreement, or a failure to comply with any provision of this Agreement, the performance of Services by Mr. Mills, unless such loss or liability is a result of the gross negligence or willful

misconduct of Mr. Mills, or occasioned wholly or in part by any act or omission of REGENXBIO. Reasonable expenses incurred by Mr. Mills (including attorneys' fees and costs) as a party to a proceeding promptly will be paid or reimbursed by REGENXBIO in advance of the final disposition of the proceeding; provided, that Mr. Mills agrees to repay such amount if it shall ultimately be determined that the standard of conduct has not been met. Costs and expenses incurred by MR. Mills in defense of a proceeding under this Section 9(a) shall be paid upon receipt by REGENXBIO of: (i) a written request for payment; (ii) appropriate documentation evidencing

{1673505.2 }

the incurrence, amount, and nature of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under applicable law made by or on behalf of Mr. Mills to repay the amounts so paid if it shall ultimately be determined that the Mr. Mills is not entitled to be indemnified by REGENXBIO.

b. During Mr. Mills' service hereunder and as a director, and at all times thereafter, during which Mr. Mills may be subject to liability, Mr. Mills shall be entitled to the protection of any insurance policies REGENXBIO maintains for the benefit of its directors and officers against all costs, charges and expenses incurred or sustained by Mr. Mills in connection with any action, suit or proceeding to which he may be made a party by reason of Executive's being or having been a director, officer or employee of REGENXBIO or any of its subsidiaries in the same manner and at the same level as provided to other directors and officers of the Company. Notwithstanding anything to the contrary herein, Mr. Mills' rights under this Section 9(b) shall survive the termination or expiration of this Agreement for any reason.

10. Limitation of Liability

IN NO EVENT SHALL MR. MILLS BE LIABLE TO REGENXBIO OR TO ANY OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, DELAY OR CONSEQUENTIAL DAMAGES, OR DAMAGES FOR LOST PROFITS OR LOSS OF BUSINESS RESULTING FROM, ARISING OUT OF, OR IN CONNECTION WITH THE SERVICES, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, REGARDLESS OF WHETHER MR. MILLS WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. IN NO EVENT SHALL MR. MILLS' CUMULATIVE LIABILITY FOR DAMAGES OF ANY TYPE TO REGENXBIO UNDER THIS AGREEMENT EXCEED FIFTY THOUSAND DOLLARS. MR. MILLS DISCLAIMS ALL WARRANTIES WITH RESPECT TO ITS SERVICES, INCLUDING THE IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE, QUALITY OF INFORMATION, SECURITY, RELIABILITY, TIMELINESS, AND AVAILABILITY OF BACKED-UP DATA. REGENXBIO IS SOLELY RESPONSIBLE FOR THE SECURITY AND INTEGRITY OF ITS DATA AND SYSTEMS.

11. Release

In exchange for certain payments and other consideration under this Agreement, the parties agree to enter into REGENXBIO's standard form employment release agreement.

12. Miscellaneous

k. **Interpretation.** Wherever any provision of this Agreement uses the term “including” (or “includes”), such term shall be deemed to mean “including without limitation” and “including but not limited to” (or “includes without limitation” and “includes but is not limited to”) regardless of whether the words “without limitation” or “but not limited to” actually follow

{1673505.2}

the term “including” (or “includes”). Any reference in this Agreement to “day(s)” or “month(s)” shall be deemed to mean calendar day(s) or calendar month(s), respectively, unless expressly provided otherwise.

l. **Governing Law; Consent to Personal Jurisdiction.** This Agreement shall be construed and governed in accordance with the laws of the State of Maryland without giving effect to conflict of law provisions. The Parties hereby submit to the exclusive jurisdiction of and venue in the District or Circuit courts located within Montgomery County, Maryland with respect to any and all disputes concerning the subject of this Agreement.

m. **Injunctive Relief.** Mr. Mills acknowledges that REGENXBIO will not have an adequate remedy at law nor will be adequately compensated by money damages for injury caused in the event that Mr. Mills breaches or threatens to breach Mr. Mills’ obligations under Section 4 of this Agreement. It is therefore agreed that REGENXBIO shall be entitled to obtain a restraining order, injunction, or decree of specific performance from a court of equity in the event of any such breach. Nothing herein shall be construed to prevent or preclude REGENXBIO from pursuing any other remedies available to REGENXBIO for any such breach.

n. **Assignability.** This Agreement shall be binding upon and inure to the benefit of each of the Parties hereto and its successors and permitted assigns. Neither Party shall have the right to assign this Agreement without the written consent of the other.

o. **Modification; Severability.** This Agreement may be varied, amended or extended only by a written agreement between the Parties that specifically refers to this Agreement. If any provision of this Agreement is held to be illegal, invalid or unenforceable in a final, unappealable order or judgment, then such provision shall be severed from this Agreement and shall be rendered inoperative; and the remaining provisions of this Agreement shall remain binding on the Parties hereto.

p. **Headings.** The descriptive headings of the sections of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.

q. **Waiver.** No failure or delay on the part of either Party in the exercise of any power or right hereunder shall operate as a waiver thereof. No single or partial exercise of any right or power hereunder shall operate as a waiver of such right or of any other right or power. The waiver by either Party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any other or subsequent breach hereunder.

r. **Counterparts.** This Agreement may be signed in two or more counterparts, each of which shall be deemed an original, with the same force and effectiveness as though executed in a single document. This Agreement may be delivered by facsimile or electronic transmission, and facsimile or electronic copies of executed documents shall be binding as original copies.

s. **Entire Agreement.** The terms and conditions herein and in the PIIA constitute the entire agreement between the Parties relating to the subject matter of this Agreement and shall supersede all previous communications between the Parties with respect to the subject matter of

{1673505.2}

6

this Agreement. Unless specifically provided for in this Agreement, this Agreement shall not modify Mr. Mills rights or obligations as a member of the Board. Neither Party has entered into this Agreement in reliance upon any representation, warranty, covenant or undertaking of the other Party that is not set out or referred to in this Agreement.

t. **WAIVER OF JURY TRIAL.** THE PARTIES HEREBY EXPRESSLY WAIVE ANY RIGHT TO A TRIAL BY JURY FOR ANY DISPUTES ARISING OUT OF THIS AGREEMENT.

[Signature Page Follows]

{1673505.2}

7

IN WITNESS WHEREOF, and intending to be legally bound, each Party hereby executes this Agreement effective as of the Effective Date.

REGENXBIO INC.

By: /s/ Patrick J. Christmas II

Name: Patrick J Christmas

Title: Chief Legal Officer

Date: June 12, 2024

/s/ Kenneth T. Mills

Kenneth T. Mills

Date: June 12, 2024

{1673505.2}

[Signature Page to Consulting Agreement]

EXHIBIT A

Scope of Work

Mr. Mills will provide services in connection with serving as an advisor to the President and Chief Executive Officer of RGENXBIO, as reasonably requested by RGENXBIO from time to time.

{1673505.2 }

Schedule 1

Equity Awards Outstanding as of June 12, 2024

Incentive Stock Options*

Grant Date	Strike Price	Options Granted	Options Outstanding	Options Exercisable	Expiration / Cancellation Date
24-Sep-2014	\$0.85	471,743	0	0	24-Sep-2024
24-Sep-2014	\$0.85	98,103	36,316	36,316	24-Sep-2024
19-May-2015	\$3.76	30,752	30,752	30,752	19-May-2025
28-Jan-2016	\$13.09	4,687	4,687	4,687	28-Jan-2026
04-Jan-2017	\$19.50	4,689	4,689	4,689	04-Jan-2027
03-Jan-2018	\$35.80	4,111	4,111	4,111	03-Jan-2028
03-Jan-2019	\$40.82	2,449	2,449	2,449	03-Jan-2029
02-Jan-2020	\$38.99	2,564	2,564	2,564	02-Jan-2030
04-Jan-2021	\$44.97	2,223	2,223	0	04-Jan-2031
03-Jan-2022	\$34.31	2,914	2,914	0	03-Jan-2032
03-Jan-2023	\$22.25	4,496	4,496	0	03-Jan-2033
02-Jan-2024	\$18.34	5,453	5,453	0	02-Jan-2034
TOTAL		634,184	100,654	85,569	

*Incentive stock options which are not vested and exercised within three months of the Effective Date will be treated for tax purposes as non-qualified stock options.

{1673505.2 }

Non-Qualified Stock Options

Grant Date	Strike Price	Options Granted	Options Outstanding	Options Exercisable	Expiration / Cancellation Date
24-Sep-2014	\$0.85	2,747	0	0	24-Sep-2024
24-Sep-2014	\$0.85	135,607	0	0	24-Sep-2024
19-May-2015	\$3.76	244,248	50,602	50,602	19-May-2025
28-Jan-2016	\$13.09	220,313	220,313	220,313	28-Jan-2026
04-Jan-2017	\$19.50	125,311	125,311	125,311	04-Jan-2027
03-Jan-2018	\$35.80	159,389	159,389	159,389	03-Jan-2028
03-Jan-2019	\$40.82	187,551	187,551	187,551	03-Jan-2029
02-Jan-2020	\$38.99	267,436	267,436	267,436	02-Jan-2030
04-Jan-2021	\$44.97	182,944	182,944	158,163	04-Jan-2031
03-Jan-2022	\$34.31	167,274	167,274	102,822	03-Jan-2032
03-Jan-2023	\$22.25	260,436	260,436	93,829	03-Jan-2033
02-Jan-2024	\$18.34	299,797	299,797	0	02-Jan-2034
TOTAL		2,253,053	1,921,053	1,365,416	

Restricted Stock Units

Grant Date	RSUs Granted	RSUs Previously Vested	RSUs Outstanding
04-Jan-2021	40,984	30,738	10,246
03-Jan-2022	35,796	17,898	17,898

03-Jan-2023	54,753	13,688	41,065
02-Jan-2024	64,103	0	64,103
TOTAL	195,636	62,324	133,312

{1673505.2}

EXHIBIT 31.1

CERTIFICATION

I, **Kenneth T. Mills**, **Curran Simpson**, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of REGENXBIO Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **May 8, 2024** **August 1, 2024**

/s/ **Kenneth T. Mills** **Curran Simpson**

EXHIBIT 31.2

CERTIFICATION

I, Vittal Vasista, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of REGENXBIO Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **May 8, 2024** **August 1, 2024**

/s/ Vittal Vasista

Vittal Vasista
Chief Financial Officer
(Principal Financial and Accounting Officer)

EXHIBIT 32.1

CERTIFICATION

In connection with the Quarterly Report of REGENXBIO Inc. (the "Registrant") on Form 10-Q for the quarter ended March 31, 2024 June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Kenneth T. Mills, Curran Simpson, President, Chief Executive Officer and Director of the Registrant, and Vittal Vasista, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their respective knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 8, 2024 August 1, 2024

/s/ Kenneth T. Mills Curran Simpson

Kenneth T. Mills Curran Simpson

President and Chief Executive Officer
(Principal Executive Officer)

Date: May 8, 2024 August 1, 2024

/s/ Vittal Vasista

Vittal Vasista
Chief Financial Officer
(Principal Financial and Accounting Officer)

This certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose. A signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant and furnished to the United States Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.